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Abstract  
The integrity of deoxyribonucleic acid (DNA) is continuously challenged by endogenous 
and exogenous DNA damaging agents. Mutagenic and cytotoxic apurinic/apyrimidinic 
(AP) sites are amongst the most frequently formed lesions in cellular DNA and their 
repair is essential for genomic stability. AP sites in humans are processed and repaired 
mainly through base excision repair (BER), which is known to be initiated either by an 
AP endonuclease 1 (APE1) that incises 5’ to the AP site or by bifunctional DNA that 
incise 3’ to the AP site.   
 
In this study, the processing of AP sites in mammals was investigated by knockout mice 
models of endonuclease eight-like DNA glycosylases (Neil1,Neil2), as well as down-
regulation of the bifuctional endonuclease three (NTH1) and tyrosyl-DNA 
phosphodiesterase 1 (TDP1) in human epithelial cervical carcinoma (HeLa) S3 cells. The 
roles of bifunctional DNA glycosylases NEIL1, NEIL2 and NTH1 in AP site processing, 
using mouse and human whole-cell extracts, were examined by biochemical activity 
assays. Another aim of this study was to investigate whether an APE1-independent repair 
pathway involving NTH1 and TDP1 exist in mammals, since a recent study demonstrated 
such a mechanism in Schizosaccharomyces pombe where Tdp1 were shown to work 
downstream of Nth1. 
 
The results obtained in this study show that APE1 is responsible for the main incision 
activity, whereas the roles of NEIL1 and NEIL2 in AP site processing were demonstrated 
to be non-essential. The product of NTH1 incision was observed in both mice and HeLa 
S3 extracts, indicating that NTH1 is also involved in AP site processing, although to a 
lesser extent than APE1. Biochemical analysis using recombinant NTH1, also 
demonstrated poor ability to process an APE1-nicked DNA substrate compared to an 
intact AP site, indicating that NTH1 most likely work upstream  of APE1, and do not 
compete with polymerase β downstream of APE1. 
 
The product of NTH1 was shown to be further processed by not only APE1, but also by 
TDP1 in both HeLa S3 cells and mice extracts, indicating that TDP1 is capable of 
working downstream of NTH1 in an APE1-independent manner and thus may serve as a 
back-up for APE1 in the repair of AP site. 
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Sammendrag 
Integriteten av deoksyribonukleinsyre (DNA) utfordres kontinuerlig av endogene og 
eksogene forbindelser. Mutagene og cytotoksiske apurinske/apyrimidinske (AP)-seter er 
blant de mest forekommende DNA-skadene og deres reparasjon er essensiell for 
genomisk stabilitet. AP-seter i humane celler blir prosessert og reparert hovedsakelig 
gjennom baseeksisjonsreparasjon (BER), som antas å bli initiert av enten AP-
endonuklease 1 (APE1) som kutter 5’ til AP setet, eller av en bifunksjonell DNA-
glykosylase som kutter 3’ til AP setet.  
 
I dette studiet ble prosesseringen av AP seter i mammalske celler undersøkt ved bruk 
knockout musemodeller av endonuklease VIII-lik DNA-glykosylaser (Neil1,Neil2), samt  
ved nedregulering av den bifunksjonell DNA-glykosylasen endonuclease three (NTH1) 
og tyrosyl-DNA fosfodiesterase 1 (TDP1) i human kreftcellelinje (HeLa S3). Rollen av 
NEIL1, NEIL2 og NTH1 i prosesseringen av AP-seter ble undersøkt ved hjelp av 
biokjemiske aktivitetsanalyser. En annen hensikt med dette studiet var å undersøke om en 
APE1-uavhengig reparasjonsmekanisme som involverer NTH1 og TDP1 finnes i 
mammalske celler. Bakgrunnen for dette var en studie som nylig demonstrerte en 
tilsvarende reparasjonsmekanisme i Schizosaccharomyces pombe som tyder på at Tdp1 
fungerer nedstrøms for Nth1. 
 
Resultatene fra dette studiet indikerer at APE1 er ansvarlig for mesteparten av 
kutteaktiviteten av AP seter, mens bidraget av NEIL1 og NEIL2 i AP-sete reparasjon, har 
mest sannsynlig ingen essensiell betydning i mammalske celler. Produktet av NTH1 
aktiviteten ble også observert i både muse og HeLa S3 ekstrakter, noe som tyder på at 
NTH1 er involvert i AP-sete reparasjon, men i noe mindre grad enn APE1. Rekombinant 
NTH1 demonstrerte dårligere evne til å prosessere et APE1-kuttet DNA substrat enn et 
intakt AP-sete. Dette tyder på at NTH1 mest sannsynlig virker oppstrøms for APE1, og 
konkurrerer ikke med polymerase β nedstrøms for APE1. 
 
Produktet generert av NTH1, ble videre prosessert av ikke bare APE1, men også av TDP1 
i både muse og HeLa S3 ekstrakter. Dette kan tyde på at TDP1 er i stand til å fungere 
nedstrøms for NTH1 på en APE1-uavhengig måte og kan derfor muligens fungere som en 
reserve for APE1 under AP-sete reparasjon.  
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1 Introduction 
The preservation of the genetic material through generations is essential for the survival 
of a species. Deoxyribonucleic acid (DNA), a stable molecule in all cells, is the carrier of 
the genetic information. However, all cells are constantly exposed to DNA damaging 
agents that threaten the integrity of the DNA (Klungland, 2001). Without DNA repair, 
damages can result in genetic instability, mutations, chromosome alterations and 
eventually cell death (Barnes et al., 1993).  
 
DNA undergoes damage from reactive metabolites that are present in the cell and from 
environmental agents such as UV or ionizing radiation and chemicals (Lindahl, 1993). 
 
Different DNA repair pathways have been identified and these pathways are often 
remarkably conserved in several species. This underscores the critical role of DNA repair 
enzymes in the cells, as well as the importance of maintaining the functional properties of 
DNA. There are an increasing number of recent studies that illustrate the importance of 
DNA repair in context with neurodegenerative diseases or cancer. A detailed 
understanding of the different repair mechanisms is thus important in order to gain insight 
in different diseases (David and Williams, 1998).  
1.1 DNA damage 
One of the most frequently formed lesions in DNA are apurinic/apyrimidinic (AP) sites, 
which have been calculated to arise at a rate of about 10,000 times in a mammalian cell 
per day (Loeb and Preston, 1986). Thus, efficient DNA repair mechanisms have evolved 
to ensure repair and to protect the cells from the damaging effects caused by cellular 
metabolites and environmental agents. These different repair processes work together in a 
complex manner coordinated by a large number of proteins and cofactors. Their proper 
functioning at different levels is therefore critical for survival and prevention of 
mutagenesis (Barnes et al., 1992).  
 
The replication and transcription machinery uses proofreading mechanisms to ensure high 
degree of accuracy in DNA replication and transcription. Because an AP site lacks a base, 
it will during replication and transcription, present a block to continued synthesis by the 
DNA polymerases or ribonucleic acid (RNA) polymerases, respectively. However, 
replication through an AP site can still occur by the action of translesion polymerases that 
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provide a certain level of tolerance towards replication blocking lesions, by incorporating 
random bases resulting in base substitutions (Lange et al., 2011;Pages et al., 2008). 
 
Thus, AP sites are harmful cellular DNA lesions that give rise to an increase in genetic 
mutations (Almeida and Sobol, 2007). The formation of AP sites in DNA are caused by 
spontaneous base loss and by the action of specific DNA glycosylases that hydrolyze the 
N-glycosylic bond between the 2’-deoxyribose and the damaged or incorrect base (Berdal 
et al., 1998). AP sites occur regardless of base type, although more frequently for purines 
(David and Williams, 1998). In addition, AP sites are also induced directly by radiation, 
reactive oxygen species (ROS) and to some extent by alkylation as well. ROS, arisen 
from normal aeorobic metabolism, can also generate oxidized DNA bases, deamination 
products, oxidized sugar fragments and DNA single strand breaks (SSB). 
 
Base residues of DNA can also undergo hydrolytic deamination, such as the deamination 
of cytosine (C) to uracil (U) (Figure 1.1) (Lindahl, 1993). It is one of the most common 
base lesions found in DNA, and occurs about 200 times in a mammalian cell per day. 
Since uracil pairs with adenine (A) during replication, this deamination will lead to 
guanine (G): C →A: thymine (T) transition mutation (Kavli et al., 2007).  
 
 
Figure 1.1. Examples of common base lesions of all four DNA bases. The AP site, generated by 
hydrolysis of the glycosylic bond, occurs regardless of base. "BASE" refers therefore to any of 
the four bases (David and Williams, 1998). 
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Oxidized DNA bases are considered to be major contributors in causing cell death and 
mutation in the genome. They have for a number of years attracted much attention in 
order to gain insight into the repair mechanisms. One of the most studied oxidized base 
lesion is the guanine oxidation product 7,8-dihydro-8-oxoguanine (8-oxoG). Oxidations 
of guanine residues tend to occur more often relative to the other DNA bases due to its 
low oxidation potential (Bjelland and Seeberg, 2003;Krishnamurthy et al., 2008;Neeley 
and Essigmann, 2006).  
 
Thus, AP sites and oxidized base residues can pose mutagenic and cytotoxic threats to the 
cells if the damages are not properly repaired. The sheer quantity of these lesions suggests 
that a tightly controlled system is necessary for accurate repair. Efficient and overlapping 
repair mechanisms are therefore required for maintaining the structural integrity of the 
genomic DNA (Loeb and Preston, 1986). 
1.2 DNA repair 
The different repair pathways are conserved defence mechanisms with overlapping 
substrate specificities that function as back-up systems for each other. Thus, various 
lesions may be repaired by different repair pathways and enzymes that may substitute for 
each other (Nilsen and Krokan, 2001). 
 
Six major groups of DNA repair mechanisms have been broadly defined. One group of 
repair mechanisms, usually referred to as “direct reversal”, eliminates DNA lesions in a 
single step process and is the simplest type of DNA repair. All the other repair processes 
involve degradation of at least the damaged base followed by DNA resynthesis. Only a 
limited number of DNA lesions can be repaired by “direct reversal” mechanisms. These 
mechanisms include for instance photoreactivation repair, direct ligation of SSB with 
unmodified termini and dealkylation by specific alkyltransferases or AlkB (Falnes et al., 
2002;Zharkov, 2008). “Nucleotide excision repair” (NER) is another repair mechanism 
which removes primarily bulky helix-distorting lesions. “Mismatch repair” corrects errors 
made by DNA polymerases during replication by removing mismatched bases, as well as 
small insertion and deletion loops from the daughter DNA strand. “Non-homologous end-
joining” (NHEJ) mechanism seals double strand breaks, whereas “homologous 
recombination” (HR) repair is involved in both repairing strand breaks and lesions that 
cannot be repaired in other ways.  
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Here focus will particularly be on the sixth type of DNA repair known as the “base 
excision repair” (BER) which deals mainly with a broad spectrum of DNA lesions 
generated in cells every day (Almeida and Sobol, 2007;Zharkov, 2008). 
1.2.1 The BER pathway 
The BER pathway is evolutionarily conserved and repairs non-bulky DNA base damages 
by removing simple base lesions derived from oxidation, alkylation and SSB. Removal of 
AP sites, arisen from a variety of exogenous and endogenous DNA damaging agents, is 
also the responsibility of BER. Importantly, AP sites function as mutagenic intermediates 
generated during the BER pathway as well. This DNA repair pathway is normally 
initiated by lesion-specific DNA glycosylases which can be divided in to three subtypes: 
a monofunctional DNA glycosylase, a bifunctional with associated β-elimination activity, 
a bifunctional with an associated β,δ-elimination activity, described in detail later. 
 
As most DNA repair processes, BER functions through a series of repair complexes that 
assemble at the site of the DNA lesion. The lesion is then processed by recruiting and 
exchanging additional proteins throughout the repair in a coordinated way that involves 
protein-protein interactions. These proteins complexes may vary depending on the 
initiating lesion or on the post-translational modifications (PTMs) of the BER proteins 
involved. But more importantly, these BER complexes also vary by the chemistry of the 
repair intermediates created during the repair. Regardless of the initiating lesion, that is 
ultimately repaired, many similarities are found among the different assembled 
complexes of BER proteins (Almeida & Sobol, 2007;Demple and Harrison, 1994;Svilar 
et al., 2011). 
 
Although there are different variants of the BER model, there are five common steps that 
always occur during BER: lesion recognition and base removal, strand scission, gap 
tailoring, DNA synthesis and ligation. BER is initiated with the recognition and excision 
of the damaged base by one of the three subtypes of DNA glycosylases, resulting in an 
AP site. The AP site, which is a substrate primarily for AP endonuclease (APE), is either 
cleaved by the activity of an APE or by the AP lyase activity of bifunctional DNA 
glycosylases that generate SSB (Figure 1.2). Removal of the AP site by either of the two 
enzymes yields different chemical intermediates and hence different BER complexes 
during the repair. This difference defines a branching point for the BER pathway, 
depending on what subtype of DNA glycosylase initiate the pathway.   
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Figure 1.2. DNA glycosylases removes damages bases and generates either AP site or a SSB. X 
represents different 3’-terminus yielded by a bifunctional DNA glycosylase with β- or β,δ-
elimination activity. Modified from (Izumi et al., 2003). 
 
The transient complexes formed after strand scission is mediated by scaffold proteins 
such as X-ray cross complementation group 1 (XRRC1) and poly (ADP-ribose) 
polymerase 1 (PARP1) (Mitra et al., 2001;Svilar et al., 2011). The precise steps of repair 
in each branch of the BER model in mammals are further described in more detail below 
(Figure 1.3). Even though each model goes through the five basic steps essential for BER, 
they still have common and unique transient protein complexes and protein-protein 
interactions that mediate the repair.  
 
Repair intiated by a monofunctional DNA glycosylase  
When BER pathway is initiated by a monofunctional DNA glycosylase in for example 
humans, it involves hydrolysis of the N-glycosylic bond to remove the damaged base. 
The resulting AP site is then removed by the enzymatic activity of the main human APE 
(APE1) that catalyzes the incision of the damaged strand 5’ to the AP site. That leaves a 
single nick containing a 3´-hydroxyl (3’OH) and a 5´-deoxyribose-phosphate (5’dRP) 
terminus at the margins. The 5’dRP lyase activity of the DNA polymerase β (POL β) 
hydrolyzes the 5’dRP terminus to produce a ligatable 5’-phosphate (5’P) terminus. POL β 
also fills the single nucleotide gap, preparing the strand for ligation by DNA ligase I 
(LIGI) or by a complex of DNA ligase III (LIGIII) and XRCC1, and thereby completes 
the repair. Notably, two of the five steps require POL β (Figure 1.3(II)).  
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Repair initiated by a bifuntional DNA glycosylase w ith associated β-
elimination  activity 
When a base lesion, usually an oxidative damaged base, is recognized by a bifunctional 
DNA glycosylase, the damaged base is excised from the DNA strand in a manner similar 
to monofunctional glycosylase as described above. However, bifunctional glycosylase 
add an additional level of complexity due to their 3’-AP lyase activity by incising 3’ to 
the AP site through a β-elimination step. That yields a SSB with a replication-blocking 
3’-phospho-α,β-unsaturated aldehyde (3’ dRP) and a 5’P terminus at the margins (Figure 
1.3(I)). The 3’-AP lyase activity is further referred also as β-elimination activity. The 
resulting nick is then tailored by the 3’-phosphodiesterase activity of APE1 which 
removes 3’dRP, thereby generating a 3’OH terminus and a single nucleotide gap. POL β 
and LIGIII/XRCC1 complex can then complete the further process by inserting the 
nucleotide and resealing the strand, respectively (Almeida and Sobol, 2007;Svilar et al., 
2011).  
 
Repair initiated by bifunt ional DNA glycosylase with associated β,δ -
elimination activity 
The third branch of the BER model has recently been characterized and is initiated by 
human DNA glycosylases named endonuclease eight-like (NEIL), discussed in detail in 
section 1.3.1. NEIL1 and NEIL2 are bifunctional DNA glycosylases with associated β,δ-
elimination activity that initiate APE1-independent repair. Actions of NEIL1 and NEIL2 
causes hydrolysis of the glycosylic bond to remove the damaged base followed by a β,δ-
elimination step that yields a 3’P terminus and releases the trans-4-hydroxy-2,4-
pentadienal. This results in a single nucleotide gap containing 5’P and 3’P at the margins 
(Figure 1.3(III)). 
 
In mammalian cells the DNA 3’-phosphatase activity of APE1 seems to be very weak 
compared to for example it’s homologues in Escherichia coli (E. coli), which can remove 
all 3’-blocking termini including 3’P (Xu et al., 2003). Since the β,δ-elimination product 
in mammals is not processed by APE1, polynucleotide kinase phosphatase (PNKP), is 
subsequently recruited to the AP site to remove the 3’P. PNKP, which is absent in E. coli 
and abundant in mammalian cells, is a bifunctional enzyme with both 5’-kinase and 3’-
phosphatase activities catalyzed by two distinct domains. This enzyme can thereby act as 
a phosphatase or kinase depending on conditions that will activate one domain to a 
greater extent than the other (Caldecott, 2002;Jilani et al., 1999). PNKP will act as a 3’-
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phosphatase during the repair pathway to remove 3’P and prepare the strand for DNA 
synthesis by POL β and ligation by LIGIII/XRCC1 complex (Wiederhold et al., 2004).  
 
Thus, the products of β,δ-elimination activity in mammalians is processed by PNKP and 
not by APE1 as in the case for the two other branches described earlier. PNKP does not 
seem to interact directly with NEIL enzymes, but it has been suggested that PNKP could 
associate indirectly with them through a large complex consisting of XRCC1, POL β and 
LIGIII (Das et al., 2006). 
  
Figure 1.3. Schematic representation of the different branches of  APE- and PNKP-dependent 
BER pathways in human cells. Each branch is (I, II, III) is defined by the type of DNA 
glycosylase that initiates the pathway. (Pathway I) After the β-elimination step of a bifunctional 
DNA glycosylase, APE1 removes the resulting 3’dRP by generating a 3’OH that can be further 
processed by POL β. (Pathway II) M = Monofunctional DNA glycosylase, generates an AP site, 
which is cleaved by APE1. POL β removes the resulting 5’dRP terminus and process the single 
nucleotide gap. (Pathway III) NEIL DNA glycosylases generates 3’P terminus, that is further 
processed by PNKP. Adapted from (Wiederhold et al., 2004).  
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1.2.2 Short-patch and long-patch BER 
A branching point has also been observed after recognition and removal of the damaged 
base that divide the BER pathway in two different subpathways: the short-patch (SP) and 
the long-patch (LP) BER. Of these two pathways, the SP-BER is currently thought to 
represent the major subpathway initiated either by a lesion-specific mono- or bifunctional 
DNA glycosylase (Almeida and Sobol, 2007). While the gap-filling step in SP-BER 
requires insertion of a single nucleotide and the action of POL β as described in section 
1.2.1, LP-BER involves removal and replacement of longer patches of 2-10 nucleotides to 
fill the gap (David and Williams, 1998).  
 
The LP-BER is initiated in a similar way to SP-
BER, but the 5’dRP is replaced as a part of single- 
stranded flap generated by the strand displacement 
DNA synthesis by POL β and polymerase δ/ε  (POL 
δ/ε) in complex with proliferating cell nuclear 
antigen (PCNA) (Figure 1.4). To complete the 
repair, flap endonuclease 1 (FEN1) processes the 
resulting 5’ flap, leaving a nick that has been 
transferred 2-10 nucleotides downstream of the 
original base lesion. 
 
The choice of whether SP- or LP-BER is initiated 
has not yet been completely understood. However, 
in mammalian cells normal AP sites are processed 
by the SP-BER, whereas LP-BER occurs in the 
presence of a 5’dRP blocking group that is 
refractory towards the lyase activity of POL β. 
Thus, the nature of the 5’ terminus at the AP site 
dictates whether SP-BER or LP-BER is initiated 
(Sung and Demple, 2006). Furthermore, whereas 
bifunctional DNA glycosylases initiate SP-BER, the 
repair initiated by monofunctional DNA 
glycosylases may follow either pathway (Fortini et 
al., 1999). 
  
Figure 1.4. Schematic illustration of 
the long-patch BER pathway. 
Adapted from (David and Williams, 
1998). 
 
  1 Introduction 
 
9 
 
Figure 1.5. SSBR subpathway where the SSB 
is induced by either a DNA glycosylase or for 
example by  ionizing radiation (IR).  AP= AP 
site; P = phosphate; dRP= deoxyribose-
phosphate  OH=hydroxyl group. Figure 
modified from (Wilson et al., 2007). 
 
1.2.3 Special cases of BER 
Over the past several years, additional alternate repair mechanisms have been described 
in both prokaryotic and eukaryotic cells that utilize many of the same proteins as BER but 
work in different combinations to repair base damage. Thus, they can be considered as 
minor subpathways of BER. For example an alternate DNA glycosylase-independent 
repair pathway defined as “nucleotide incision repair” (NIR) is initiated by APE1 instead 
of DNA glycosylases in repair of oxidized pyrimidines and α-deoxynucleotides (Zharkov, 
2008). APE1 cleaves 5’ to the lesion, in the same manner as during regular BER, but it 
bypasses the DNA glycosylase step. That generates a 3’OH end and a 5’P end which also 
contains the damaged nucleotide, making the 5’end unable to be processed by the 5’dRP 
lyase activity of POL β. Thus, the repair proceeds via LP-BER (Sung and Demple, 2006).  
 
The biological importance of NIR remains unclear, but it 
has been argued that NIR allows the cell to avoid the 
formation of toxic AP site intermediates, although SSB 
generated during NIR may be as toxic as an AP site 
(Ischenko and Saparbaev, 2002).  
 
In addition, the SSB repair (SSBR) pathway utilizes many 
of the same proteins as BER such as APE, POL β, LigIII 
along with scaffold proteins PARP1 and XRRC1 (Figure 
1.5). SSBR is responsible for mainly the repair of SSB in 
DNA caused by ROS, irradiation or incomplete 
topoisomerase action (Almeida and Sobol, 2007 
;Friedberg, 2006). The initiation step is the main 
difference between regular BER pathway and SSBR. 
PARP1 recognizes the SSB, thereby signaling recruitment 
of repair proteins to the damaged site (Caldecott et al., 
1996). In both BER and SSBR, repair may occur at a 
single nucleotide level or as a longer patch of repair. In 
addition these two repair pathways have common gap-
filling and nick sealing steps, but SSBR also involves 
several end-processing enzymes which is perhaps the most diverse enzymatic step in BER 
and SSBR due to the variety of termini generated (Hegde et al., 2012).  
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1.2.4 Role of tyrosyl-DNA phosphodiesterase 1 in APE-independent repair 
In section 1.2.1, an APE-independent BER pathway initiated by a DNA glycosylases with 
associated β,δ-elimination activity was described. Recent studies confirm that APE-
independent BER pathways play an important role in the regulation of DNA repair 
mechanisms.  
 
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a 68.5 kDa repair enzyme and was 
discovered in Saccharomyces cerevisiae.  Tdp1 is a member of the phospholipase D 
superfamily which includes a diverse group of enzymes that catalyzes the cleavage of the 
phosphodiester bond on different substrates ranging from phospholipids to DNA 
(Interthal et al., 2001). Tdp1 catalyzes primarily the cleavage of protein-DNA complexes 
by hydrolysis of a phosphodiester bond between an O-4 atom of tyrosine residues and a 
DNA 3’-phosphate. This type of linkage, a 3’-phosphotyrosine linkage, is typical for the 
transient covalent intermediate produced by the action of topoisomerase 1 (Top1) upon 
cleavage of a DNA strand (Lebedeva et al., 2011;Yang et al., 1996).  
 
The enzymatic activity of Tdp1 was proposed to be associated with the repair of DNA 
lesions that developed from irreversible Top1-DNA cleavage complex (Yang et al., 
1996). Top1 is a ubiquitous enzyme that relaxes positive and negative supercoiling in 
DNA and thereby regulates the DNA topology. 
 
Generation of a covalent complex between Top1 and DNA requires a reversible 
transesterification reaction (Figure 1.6). This transient DNA strand break, produced upon 
formation of Top1-DNA complex, allows removal of any local helical tension and 
thereby relaxes the DNA. Once this happen, the covalent intermediate is reversed by a 
second transesterifiaction reaction. Under normal circumstances, the transient break in 
DNA caused by Top1-DNA complex will get resealed since the rate of religation is much 
greater than the rate of cleavage (Champoux, 2001;Dexheimer et al., 2008). However, 
different conditions or chemicals such as camptothecin (CPT) can reduce or inhibit the 
religation reaction. If this transient break in DNA is not resealed, the SSB caused by Top1 
linkage to the DNA, will get transformed into a prolonged double-stranded (ds) break 
followed by a collision of the replication fork (Dexheimer et al., 2008;Pommier et al., 
2006). 
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Figure 1.6. Reversible transesterification reaction that generates a covalent complex between 
Top1 and DNA that removes helical tension and relaxes the DNA (Dexheimer et al., 2008). 
 
The enzymatic activity of Tdp1 requires prior denaturation of the Top1 bond to DNA 
which presumably results in enhanced steric access of the phosphodiester bond. Thus, it 
has been suggested that in order to maintain efficient Tdp1 activity Top1 must go through 
proteolysis. This is in agreement with studies demonstrating that the efficiency of Tdp1 
processing increases as the length of Top1 polypeptide is shortened by the ubiquitin-
proteosome pathway (Debethune et al., 2002;Dexheimer et al., 2008). 
 
The efficiency of Tdp1 activity is not only constricted to Top1-DNA complex or single 
tyrosine residues, although Tdp1 is less efficient with other substrates. Indeed, recently it 
was suggested that Tdp1 in Schizosaccharomyces pombe (S. pombe) act in an APE-
independent branch of BER by removing the 3’dRP generated by bifunctional DNA 
glycosylase Nth1 (Nilsen et al., 2012). The broad substrate specificity of Tdp1 is also 
demonstrated with the analysis of recombinant human Tdp1 (TDP1) which is capable of 
processing the 3’dRP terminus to 3’P terminus (Lebedeva et al., 2011). In addition, 
analysis of TDP1 has also shown to hydrolyze other 3’-blocking lesions including 3’-
phosohoglycolates, indicating that it may function as a general 3’-phosphodiesterase as 
well as a repair enzyme (Dexheimer et al., 2008). 
 
Furthermore, the 3’P terminus generated by TDP1 is further hydrolyzed to a 3’OH by the 
3’-phosphatase activity of PNKP. The 3’OH terminus is then extended by a DNA 
polymerase. TDP1 has been shown to exist in complex with PNKP in human cells 
suggesting that TDP1 and PNKP function in the same repair way (Figure 1.7) (Lebedeva 
et al., 2011;Plo et al., 2003).   
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The importance of TDP1 is underscored by the fact that that a recessive mutation in 
TDP1 gene is responsible for inherited neurodegenerative disorder, further discussed in 
section 1.4 (Takashima et al., 2002). 
 
 
Figure 1.7. Tdp1-initiated repair of an irreversible Top1-DNA complex (Dexheimer et al., 2008). 
 
1.3 Major BER enzymes 
Most of the BER enzymes that had been characterized in the early 1990’s, provided an 
insight into mechanisms of lesion recognition and catalysis (Zharkov, 2008). Several 
DNA glycosylases and other BER proteins have been mentioned in previous sections 
without any further introduction. Thus, in this section, major BER enzymes will be 
described in more detail.  
1.3.1 DNA glycosylases 
Recognition of DNA damage in highly condensed chromatin is a critical step specially 
when the structures of the oxidized base lesions are not significantly different from the 
original base and almost normal basepairing is achieved with only minor perturbations in 
the DNA helix (Hegde et al., 2010). Since DNA glycosylases initiate BER, their presence 
is essential to the recognition and removal of DNA base lesions. Their mechanism of 
actions has been extensively studied on a number of different levels. Regulation of DNA 
glycosylase activity via protein-protein interactions facilitate lesion recognition and 
ensure that initiated repair is completed through formation of lesion-specific repair 
complexes (Almeida and Sobol, 2007). While alkylated bases and uracil are excised by 
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monofunctional DNA glycosylases, all oxidized bases are removed by bifuntional DNA 
glycosylases with lyase activity (Mitra et al., 2001).  
 
DNA glycosylases utilize a mechanism of base excision that involves extrahelical 
flipping of modified, damaged or even normal base into the catalytic pocket of the 
enzyme. Thus, DNA glycosylases specificity depends on how the substrate lesion fits into 
the binding pocket and where the binding is stabilized by different types of interactions 
(Slupphaug et al., 1996). However, since a large number of lesions are excised by the 
eleven DNA glycosylases in mammalian cells, the DNA glycosylases usually possess 
rather broad substrate specificities. In spite of this, DNA glycosylases also have distinct 
preferences and back-up functions (Hegde et al., 2008;Hildrestrand et al., 2009). 
 
Furthermore, the overlapping substrate specificity of DNA glycosylases is most likely due 
to the fact that catalytic pockets of DNA glycosylases allows induced fit for the different 
substrates. This is also consistent with the general observation that the individual 
requirement of a specific DNA glycosylase is not essential for the general repair, nor is 
the deficiency of a specific DNA glycosylase lethal in most cases (Hegde et al., 
2012;Klungland et al., 1999).  
 
There has been some discussion about how DNA glycosylases are able to detect base 
lesions within the DNA helix. Questions like whether the DNA glycosylases actively 
contributes to baseflipping and if the damaged or even the normal bases are passively 
trapped into the catalytic pocket of the enzymes, have been raised. The last few years a 
number of studies have tried to answer these questions without being able to determine 
how DNA glycosylases search for and detect base lesions. There has however been 
suggested a passive role for DNA glycosylases in the baseflipping mechanism, where 
DNA glycosylases may catch the flipped base during a scanning process (Cao et al., 
2004;Dalhus et al., 2009). Further experiments are clearly needed to clarify the details. 
 
Currently most of the DNA glycosylases can be divided into three main superfamilies as 
described in greater detail below. However, there are several DNA glycosylases that do 
not belong to any of the three superfamilies. Each superfamily is organized around one or 
more core families that are characterized by a number of motifs and folds that are present 
in most members of the superfamilies (David and Williams, 1998;Zharkov, 2008). 
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Uracil DNA glycosylase superfamily  
Uracil DNA glycosylase superfamily consists of at least five families of enzymes with 
similar substrate specificities, but low sequence similarities. The Udg family-1 DNA 
glycosylases are the most widely distributed members of this superfamily, and remove the 
main fraction of uracil from genomic DNA. Uracil DNA glycosylases (e.g. Ung in  
E. coli, UNG in humans and Ung1p in yeast) function by excising uracil from both 
single-stranded (ss) and ds DNA and do not produce breaks after base excision. However, 
they are inactive towards pyrimidines in DNA as well as uracil in RNA (David & 
Williams 1998;Zharkov, 2008). 
 
Fpg/Nei superfamily 
The superfamily of formamidopyrimidine DNA glycosylase (Fpg) and endonuclease 
eight (Nei) consists of homologous E. coli enzymes. Both are bifunctional DNA 
glycosylases with associated β,δ-elimination activity . Human DNA glycosylases named 
NEIL1 and NEIL2, mentioned previously, belongs to the same familiy as E. coli Fpg and 
Nei (Bandaru et al., 2002). NEIL enzymes initially recognized oxidized pyrimidines like 
5-hydroxyuracil (5-OHU), but was later observed to efficiently excise oxidized purines as 
well, such as 8-oxoG (Krishnamurthy et al., 2008). In addition, NEIL enzymes have been 
to be more active with ss DNA as present in a bubble or a fork. Thus, NEIL enzymes 
preferentially function in the repair during DNA replication or transcription (Dou et al., 
2003). Table 1.1 summarizes a list of some base lesions recognized and removed by 
NEIL1 and NEIL2. 
Table 1.1. Oxidized base lesions recognized and removed by human bifunctional DNA 
glycosylase NEIL1 and NEIL2 with associated β,δ-elimination. Adapted from (Svilar et al., 2011). 
Gene 
symbol 
Gene name Gene ID Uniprot 
accession 
number 
Organelle 
expressed 
Known substratea 
NEIL1 endonuclease 
eight (VIII)-
like 1   
79661  Q96FI4 Nucleus, 
cytoplasm 
and 
mitochondria 
5-hyroxy-C; 5-hydroxy-U:A/T>G  
Guanidinohydantoin/ Spiroiminodihydantoin 
(double- and single-stranded) 
Iminoallantoin (double- and single-stranded) 
5,6-Dihydro-T  
5,6-Dihydro-U:G/C/A>T  
2,6-diamino-4-hydroxy-5-formamidopyrimidine 
(FapyG):C  
7,8-dihydro-8-oxoguanine (8-oxoG):C/G>T>A  
4,6-diamino-5-formamidopyrimidine (FapyA):T  
NEIL2 Nei 
endonuclease 
eight 
(VIII)-like 2   
252969 Q969S2 Nucleus and 
cytoplasm 
5-hydroxy-U:G>T>A 
 5-hyroxy-C  
5,6-Dihydro-U:G/A  
7,8-dihydro-8-oxoguanine (8-oxoG):C/A  
Guanidinohydantoin/ Spiroiminodihydantoin 
(double- and single-stranded) 
Iminoallantoin (double- and single-stranded) 
aReferences: (Bjelland and Seeberg, 2003;Hailer et al., 2005)  
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Nth superfamily 
The family of DNA glycosylases related to endonuclease three (Nth) is the most diverse 
group of DNA glycosylases (Zharkov, 2008). The originally identified activity of Nth, 
encoded by the nth gene in E. coli, was DNA strand scission. However, it was soon 
recognized that Nth had both DNA glycosylase activity and AP lyase activity that cleaved 
the phosphodiester backbone 3’ to an AP site. 
 
This family of bifunctional DNA glycosylases has the widest substrate specificity 
amongst BER glycosylases, and is also specific for a large number of oxidized 
pyrimidines including thymine glycol (Tg) and urea. Most of these substrates derive from 
oxidative reactions at the 5,6-double bond in thymine or cytosine such as Tg and 5-
hydroxycytosine (5-OHC). However, they are mainly known to be active upon ds DNA 
(David and Williams, 1998;Katcher and Wallace, 1983). 
 
It is important to underscore the fact that many of the DNA glycosylases such as human 
endonuclease three- like 1 (NTH1) and NEIL have overlapping substrate specificities, and 
therefore often processes the same substrates (Hegde et al., 2012). Some lesions 
processed by NTH1 in humans, are listed in Table 1.2. 
 
Table 1.2. Oxidized base lesions recognized and removed by human bifunctional DNA 
glycosylase NTH1 with associated β-elimination. Adapted from (Svilar et al., 2011) 
Gene 
symbol 
Gene name Gene ID Uniprot 
accession 
number 
Organelle 
expressed 
Known substratea 
NTHL1 
(NTH1) 
endonuclease 
three (III)-like 
1  
4913 P78549 Nucleus and 
mitochondria 
T-glycol 
C-glycol 
4,6-diamino-5-formamidopyrimidine 
(FapyA) 
5,6-dihydro-U:G/A  
5-formyl-U  
5,6-dihydroxy-C  
5,6-dihydro-T  
urea  
5-hydroxy-U:G  
5-hydroxy-C:G>A 
5-hydroxy-5,6,-dihydro-T  
7,8-dihydro-8-oxoguanine (8-oxoG) 
aReferences: (Bjelland and Seeberg, 2003;Matsumoto et al., 2001) 
 
Since the discovery of Nth in E. coli, similar enzyme homologues have been identified in 
different organisms including yeast and mammals (Gossett et al., 1988;Higgins et al., 
1987). Ntg1p and Ntg2p in yeast and NTH1 in humans are close homologues to E. coli 
Nth with similar substrate specificities and extensive sequence similarities (David and 
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Williams, 1998). The NTHL1 gene encodes NTH1 with an open reading frame that 
translates a protein of 34.3 kDa and 312 amino acids (Aspinwall et al., 1997). 
 
The crystal structure of E. coli Nth consists of two α-helical domains which contain a 
helix-hairpin-helix motif, and an iron-sulfur cluster (Kuo et al., 1992). According to 
several recently studies the iron-sulfur cluster plays a role in DNA binding, but does not 
participate in catalysis (Fromme and Verdine, 2003). DNA binds to the binding pocket of 
the enzyme between the two domains while a single lysine residue (Lys-120) and an 
aspartic residue (Asp-138) in the active site catalyzes the reaction. When the enzyme 
carries out β-elimination, it forms a Schiff base between the active site Lys-120 and the 
deoxyribose in DNA formed after base excision (Dodson et al., 1994). A three-
dimensional structure of Nth in a complex with damaged DNA is presented (Figure 1.8).  
 
 
Figure 1.8. A three-dimensional structure of E. coli Nth with the two domains in blue and green. 
The iron-sulfur cluster is shown in yellow and rust, respectively.  The duplex DNA is shown in 
gold with the lesion nucleoside in grey and the complementary estranged nucleoside in red 
(Fromme and Verdine, 2003).  
 
Compared to DNA glycosylases homologues in lower organisms, mammalian DNA 
glycosylases possess unique structural features such as an unfolded extension or a tail 
which participate in protein-protein interactions (Hegde et al., 2010;Sarker et al., 1998). 
The sequence alignment of NTH1 with E. coli Nth for instance revealed an N-terminal 
extension segment of 10 kDa in NTH1 which is absent in E. coli (Figure 1.9). The N-
terminal segment is however not required for the enzymatic activity. It has although been 
demonstrated that the N-terminal segment may affect the glycosylase activity by 
increasing the enzymes affinity towards the DNA product generated after the glycosylase 
and lyase activity. Such terminal extentions with unconserved polypeptide sequence are 
not unusual amongst mammalian glycosylases or APEs (Izumi et al., 2003;Liu and Roy, 
2002).   
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Figure 1.9. Simplified illustration of E. coli Nth and NTH1, showing extensions. Boxes and lines 
indicate conserved and unconserved segments, repectively. Total amino acids are shown at right 
and the number with arrow define the border between the conserved and unconserved segments 
(Izumi et al., 2003).  
 
Until recently, excision of the base by a DNA glycosylase and catalysis to generate a β-
elimination product were thought to occur subsequently. However, studies with 
bifunctional glycosylases such as NTH1 suggest that this not may be the case. Studies of 
NTH1 where activity and binding affinity to Tg-containing DNA were investigated 
revealed enhanced glycosylase activity and abrogation of the NTH1’s β-elimination 
activity upon activation of APE1. This was supported by the fact that only the product of 
APE1, 5’dRP, was detectable not the product of β-elimination. Therefore, under 
physiological conditions where APE1 is abundant, NTH1 may act as a monofunctional 
glycosylase on Tg:A damaged DNA, thereby circumventing the β-elimination step and 
forwarding the damage directly towards cleavage by APE1 which has a greater capacity 
to cleave 5’ to the AP site than 3’ to the β-elimination product (Almeida and Sobol, 
2007;Marenstein et al., 2003). 
 
Studies with other DNA glycosylase such as 8-oxoguanine DNA glycosylase (OGG1) 
showed similar results, suggesting that the circumvention of the β-elimination upon 
activation of APE1 is commonly observed for bifunctional glycosylases in vivo (Vidal et 
al., 2001).  
1.3.2 AP endonuclease 
The second step in BER process after base excision is catalyzed by APEs that recognizes 
the AP sites and incises the DNA 5’ to the AP site. Not only do they incise DNA at AP 
sites, but they also efficiently removes the products of β-elimination to produce 3’OH 
terminus required for the gap-filling step by a DNA polymerase (Wiederhold et al., 
2004). In human cells, APE1 is responsible for more than 95% of the AP site incision 
activity, underscoring its importance in AP site repair (Chen et al., 1991). In addition, 
APE1 possesses a number of minor functions as 3’-phosphatase, 3’-phosphoglycosylase, 
3’-phosphodiesterase and 3’→5’ exonuclease activities (Almeida and Sobol, 2007). 
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In general, one or two AP endonucleases are present in each organism, and they can in 
turn be divided into two groups. Exonuclease three (Xth) and endonuclease four (Nfo) are 
two E. coli enzymes which are the prototypic members of these two groups. Although 
they share similar functions, they are unrelated on a structural level. The major human AP 
endonucleases, APE1 and APE2 are both Xth’s homologues. Xth and its homologoues are 
described as metalloenzymes that relies on Mg2+ to be fully active (Zharkov, 2008).  
 
Many of the different functions of APE described above are important in the repair 
pathways since they are involved in the gap-tailoring step of the 3’-blocked terminus, 
although the efficiency of each enzymatic activity may vary in different organisms. APE1 
also interact physically with a number of BER proteins such as LIGI and LIGIII, FEN1, 
PCNA, POL β and most importantly XRRC1. By physically interacting with XRCC1, 
APE1 enhances the rate of endonucleolytic incisions and coordinates AP site repair 
initiation with other gap-tailoring enzymes (Almeida and Sobol, 2007).  
1.3.3 POL β- a DNA polymerase and a 5’dRP processing enzyme 
The major 5’dRP removing activity in mammals belongs to the classical BER enzyme 
POL β. Although POL β seems to be responsible for the primary 5’dRP lyase activity in 
mammalian BER, both DNA polymerase lambda (POL λ) and DNA polymerase iota 
(POL ι) have also been shown capable of removing the 5’dRP lesion subsequent to APE1 
strand cleavage, however much less efficiently. POL ι and POL β are the main gap-filling 
DNA polymerases involved in DNA resynthesis in eukaryotes. However, POL δ or POL ε 
also play an important role in DNA resynthesis, especially in LP-BER (Bebenek and 
Kunkel, 2004;Zharkov, 2008). 
1.3.4 DNA ligases 
The reaction which completes BER by resealing the single-stranded nick in DNA is 
catalyzed by DNA ligases. All cells possess at least one type of DNA ligase that is 
required for joining of Okazaki fragments during replication. In addition, these enzymes 
are involved in most aspect of DNA metabolism and use the energy relieved in hydrolysis 
of phosphoanhydrid to make a phosohodiester bond. Most of the DNA ligases are ATP 
dependent, while some for instance in E. coli are NAD+ dependent. Human genomes 
contain three genes for DNA ligases; LIGI, LIGIII and LIGIV. LIGIII encodes two 
isoforms of the mature enzyme, DNA ligase IIIα (LIGIIIα ) and DNA ligase IIIβ 
(LIGIIIβ). LIGIIIα is ubiquitously expressed while LIGIIIβ in only found in testes. 
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LIGIIIα seems to be predominant in SP-BER, while LIGI is the main ligase involved in 
LP-BER and replication (Tomkinson et al., 2006;Zharkov, 2008).  
1.3.5 Scaffolds proteins in BER 
The major BER enzymes discussed above constitute a core BER pathway and they are 
sufficient to successfully repair damage in vitro. However, several accessory proteins 
such as XRRC1, PARP1 and PARP2  usually functions as a scaffold for these core 
enzymes and stimulate the BER pathway in vitro and are most likely involved in BER 
processes in vivo. XRRC1 is probably the most important BER scaffold protein and is 
necessary for normal functioning BER pathways. It interacts with most, if not all, 
components of BER. Scaffolds proteins in general are believed to be involved in every 
step of the BER pathways effecting the recruitment of the core BER enzymes by 
generating multiprotein complex intermediates (Zharkov, 2008). 
 
1.4 BER in context with genomic instability and diseases.  
There is increasing evidence that BER is involved in repair of age-associated and 
neurodegenerative diseases, as well as cancer. Mouse whole-cell extracts and cellular 
knockout and knockdown models have been major tools for investigating and 
understanding the cellular and biological role of many BER proteins beyond the 
biochemical characterization of substrate specificity. There can however be differences in 
cellular response between mouse and other mammalian cells, as well as different response 
from different organs in general (Almeida and Sobol, 2007).  
 
Mice models are also widely used in research to study human genes and diseases since 
99% of the human genes are known to be conserved in mouse (Rosenthal and Brown, 
2007). In fact, recently studies of DNA glycosylase deficient mice did not demonstrate 
significant increased cancer frequencies or mutation rates. In addition, no severely altered 
phenotypes or genomic instability was observed. This might be due to overlap in 
functions between DNA glycosylases as well as the fact that other alternative pathways 
may take over the repair. One exception was however observed in OGG1-deficient mice 
that exhibited up to 6-fold higher spontaneous mutation frequency in some tissues.  
 
Cancer and genomic instability have also been demonstrated in mouse models where at 
least two DNA glycosylases were knocked out. In addition, deletion or deficiency of 
enzymes that work in steps downstream of DNA glycosylases are lethal in many cases 
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(Friedberg and Meira, 2000;Nilsen and Krokan, 2001). This has been demonstrated in 
knockout mouse models of Ape1 and Pol β (Zharkov, 2008).  
 
Imbalances of BER proteins have also been demonstrated to significantly affect the rates 
of spontaneous mutation. Overexpression could lead to the removal of normal, non-
damaged bases (Nemec et al., 2010). Mutations in BER enzymes or other repair enzymes 
can also be a critical factor in development of diseases. A homozygous mutation in 
human TDP1 gene results in a histidine to arginine mutation in the active site of TDP1. 
This mutation leads to the rare autosomal recessive neurodegenerative disease, 
spinocerebellar ataxia with axonal neuropathy (SCAN1). In contrast to other diseases 
associated with defective repair enzymes, SCAN1 patients do not have increased cancer 
frequency, but develop symptoms that are restricted to nervous system during puberty 
(Takashima et al., 2002). In addition, it has also been demonstrated that OGG1 is often 
mutated in Alzheimer’s disease patients, leading to reduced repair and increased oxidative 
damage in brain tissue (Zharkov, 2008). 
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1.5 Aims of this study 
The overall aim of this project was to gain further insight into processing of AP sites in 
mammalian cells. Better understanding of DNA repair pathways and mechanisms might 
contribute to understand the causes of human diseases and hence improve the 
development in treatment strategies. Thus, gene targeted mouse models and down-
regulation of targeted protein in human cells have been extensively used to study the roles 
of proteins involved in BER.  
 
In this study the role of NEIL1 and NEIL2 in processing of AP sites was elucidated by 
using human immortal cell lines and knockout (KO) mice of Neil1 and Neil2. The use of 
KO mice and human cell lines also made it possible to further investigate and map the 
contribution of NTH1, which represent the only remaining bifunctional DNA glycosylase 
working on oxidized pyrimidines, in the absence of NEIL enzymes (Takao et al., 2002). 
 
In addition, Nilsen et al., 2012 recently showed that Nth1 provides the major AP site 
incision activity in S. pombe and that the generated 3’dRP is further processed to 3’P by 
the actions of Tdp1. Tdp1 working downstream of Nth1 in S. pombe was an interesting 
discovery and indicated an important back-up repair pathway of AP sites in S. pombe. An 
interesting question was whether a similar mechanism also is present in mammalian cells. 
Thus, one of the aims of our study was also to examine whether similar APE-independent 
repair pathway involving TDP1 and NTH1 could be observed in mammalian cells. 
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2 Materials 
 
2.1 Bacterial strains 
Strain Characteristics Genotype Manufacturer 
BL21 Codon 
Plus RIL 
E. coli B F
– ompT hsdS(rB– mB–) dcm+ Tetr gal 
λ(DE3) endA Hte [argU ileY 
leuW Camr] 
Stratagene 
 
2.2 Plasmid 
Plasmid Manufacturer 
pET28b Novagen 
 
2.3 Enzymes 
Enzyme Buffer Manufacturer 
Uracil DNA glycosylase (Udg) 5xReaction buffer  Biolabs New England  
Endonuclease III (Nth)  5xReaction buffer Biolabs New England 
T4 polynucleotide kinase 10xT4 Polynucleotide Kinase 
Reaction buffer 
Biolabs New England 
TURBO™ DNase 10xTURBO™ DNase buffer Ambion 
 
2.4 Antibody 
Antibody  Host Dilutions  Manufacturer  
Anti-TDP1 Antibody Rabbit  1:2,000 Novus biological 
Anti-NTH1 Anti body Rabbit  1:500 Novus biological 
Anti-beta Actin antibody - Loading Control Rabbit  1:2,000 AbCam 
Goat polyclonal Secondary Antibody to Rabbit 
IgG - H&L (HRP) 
Goat 1:30,000 AbCam 
 
2.5 Primers 
Primers id
1
 Discription Sequence  5`→ 3` 
14847 Forward, NTHL1  GATGGCACACCTGGCTATG  
14848 Revers, NTHL1   GTCTCCTCTGGGGACTTGGT  
13162 Forward, ACTB  CCCTAACACCAGCCTAACCA  
13161 Revers, ACTB   GGGCTAGAGAAAAATTTGGAGAAGT 
1 Primers id is provided by the common primer database at Rikshospitalet, Oslo University hospital. 
 
2.6 Cell types 
Cell type Description  Source
1
 
HeLa S3 Human cervical carcinoma LGC promochem /ATCC 
HaCaT  Human immortalized keratinocytes LGC promochem /ATCC 
1 American Type Culture Collection (ATCC) 
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2.7 siRNA 
siRNA  Maufacturer Concentrations 
NTHL1-siRNA  Santa Cruz Biotech 10 µM 
TDP1-siRNA  Santa Cruz Biotech 10 µM 
Control siRNA  Santa Cruz Biotech 10 µM 
 
2.8 Isotopes 
Isotopes Description  Specific Activity Concentration Manufacturer 
[γ-32P]ATP  Adenosine triphosphate 
[γ-32P], NEG502A 
3000Ci(111TBq)/mmol 10mCi/mL Amersham  
[α
32P]dATP Deoxyadenosine 5'-
triphosphate, 3'-[α-
32P]- (Cordycepin 5'-
triphosphate)  
5000Ci(185TBq)/mmol 10mCi/mL Perkin Elmer 
 
2.9 DNA substrates 
Sequence 
length 
DNA damage Sequence
1
 5’→3’ 
40 mer 5-OHC GCATGCCTGCACGG[5-OHC]CATGGCCAGATCCCCGGGTACCGAG  
40 mer U GCATGCCTGCACGG[U]CATGGCCAGATCCCCGGGTACCGAG  
40 mer 5-OHU GCATGCCTGCACGG[5-OHU]CATGGCCAGATCCCCGGGTACCGAG  
40 mer Tg  GCATGCCTGCACGG[Tg]CATGGCCAGATCCCCGGGTACCGAG  
20 mer Phosphotyrosine CTACGTCAGATCTGAGGATG-pTyr 
24 mer U GGCGGCATGACCC[U]GAGGCCCATC  
1Listed DNA substrates and their complementary strands were purchased at: The Midland Certified Reagent 
Company, Incorporated.  
 
2.10 Molecular markers 
Standard  Manufacturer 
MagicMark™ XP Western Protein Standard Invitrogen 
SeeBlue® Plus2 Prestained Standard (1x) Invitrogen 
GeneRuler™ DNA Ladder Mix Thermo Scientific 
 
2.11 Kits 
Kit Manufacturer Section 
PCR Mycoplasma Test Kit  PromoKine 3.2.4 
Immun-Star™ WesternC™ Kit BioRad 3.4.1 
High capacity RNA-to-cDNA Kit Applied Biosystems 3.4.2 
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2.12 Softwares 
 
2.13 Mice 
Genotype  Strain Manufacturer
1
 
Wild-type Black-six C57BL/6 Charles River 
Neil1 single KO (Neil1-/-) Black-six C57BL/6 Laboratory 
Neil2 single KO (Neil2-/-) Black-six C57BL/6 Laboratory 
Neil1/Neil2 double KO 
(Neil1-/-Neil2-/-) 
Black-six C57BL/6 Laboratory 
1KO mice were generated in the laboratory by others (Unpublished material). Animal experiments were approved by 
the National Animal Research Authority (NARA) in Norway. Mice were housed and handled in accordance with the 
European Council Directive.  
 
2.14 Buffers and solutions 
Ordered by sections. Recipes are given in Appendix A. 
Buffers and solutions Section 
LB-sorbitol medium 3.1.1 
Buffer A/B/C 3.1.2 
Coomassie Blue stain solution 3.1.3 
Destaining solution ” 
Culture medium 3.2.1 
Cryomedium 3.2.3 
Protein-cracking buffer 3.3.1 
Lysis buffer 3.3.3 
PBS-Tween buffer 3.4.1 
PBS buffer “ 
Stripping buffer “ 
5xReaction buffer 3.5 
Dilution buffer ” 
20xTaurine buffer ” 
Tris-sucrose/MOPS buffer ” 
5x TDP1 buffer ” 
1xTBE ” 
Formamide loading dye ” 
 
  
Software  Source Section  
Image Lab Biorad 3.4.1 
StepOne™ Software v2.1 Applied biosystems 3.4.2 
Typhoon Scanner Control Amersham Biosciences 3.5 
ImageQuant TL Amersham Biosciences 3.5 
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2.15 Chemicals  
In alfabetical order 
Chemicals/ Reagents
1
 Purity/ 
Concentrations 
Manufacturer 
β-mercaptoethanol >99% Sigma Aldrich 
Acetic acid 100% Merck 
Ammoniumpersulphate (APS) (s) - BioRad 
Betaine hydrochloride (s) >99% Sigma Aldrich 
BioRad Protein Assay 5x BioRad 
Boric acid >99.5% Fluka 
Bovine Serum Albumin (BSA) 10 mg/ml BioLabs® Inc. 
Bromophenol Blue (s) - Sigma Aldrich 
Chloroform >99.8% Sigma Aldrich 
Coomassie blue (s) - Sigma Aldrich 
Dimethyl sulfoxide (DMSO) >99.5% Sigma Aldrich 
Difco Luria Bertani (LB)-Broth - Miller 
Dulbecco's Modified Eagle Medium with 4.5 g/l 
Glucose (DMEM) 
- Lonza 
Dithiothreitol (DTT) (s) - Sigma Aldrich 
Ethanol 100% Kemityl 
Ethylenediaminetetraacetic acid 
 (EDTA) 
>98% Sigma Aldrich 
Fetal Bovine Serum (FBS) - PAA Laboratories GmbH 
Formamide >99% Sigma Aldrich 
GlutaMAX™ 100x Gibco Invitrogen 
Glycerol >99.5% Sigma Aldrich 
Hepes (pH 7.4) (s) - Saveen Werner 
Hydrogen chloride (HCl) >99% Sigma Aldrich 
Imidazole (s) >99% Sigma Aldrich 
IPEGAL® CA-630 - Sigma Aldrich 
Isopropanol 99.8% Merck 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) (s) >99% Sigma Aldrich 
Kanamycin (s) 50 mg/ml Sigma Aldrich 
Lipofectamine™ RNAiMAX - Invitrogen 
Long Ranger™ Gel Solution - Lonza 
Magnesium chloride (MgCl2) (s) >98% Sigma Aldrich 
Methanol 98.5% VWR 
Myricetin (s) >96% Sigma Aldrich 
3-(N-morpholino) propanesulfonic acid (MOPS) 
buffer (s) 
>99.5% Sigma Aldrich 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) 99% Sigma Aldrich 
Ni-NTA agarose 50% Qiagen 
NuPAGE® LDS Sample Buffer  4x Invitrogen 
NuPAGE® MOPS SDS Running Buffer 20x Invitrogen 
NuPAGE® Transfer Buffer  20x Invitrogen 
Penicillin-streptomycin  (Pen-Strep) 5000 U Pen/ml  
5000 U Step/ml 
Lonza 
Phenyl methane sulfonyl fluoride (PMSF) (s) - Applichem 
Potassium chloride (KCl) - Sigma Aldrich 
Proteinase K (s) - Sigma Aldrich 
Power SYBR® Green, PCR master mix  Applied Biosystems 
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Skim milk Powder - Fluka 
Sodium acetate  - Sigma Aldrich 
Sodium borohydride (s) 90% Sigma Aldrich 
Sodium chloride (NaCl) (s) >99% Sigma Aldrich 
Sodium Deoxy cholate (DOC) >97% Sigma Aldrich 
Sodium dodecyl sulphate (SDS) 99% Sigma Aldrich 
Sodium hydrogen phosphate dehydrate 
(Na2HPO4) (s) 
>99% Merck 
Sodium hydroxide (NaOH) (s) >99% Merck 
Sodium orthovanadate (s) 99.8% Sigma Aldrich 
Sorbitol (s) - VWR 
SYBR® Safe DNA gel stain - Lonza 
Taurine (s) >99% Sigma Aldrich 
Transfer RNA (tRNA)  10 mg/ml Ambion 
Tris Base (s) - Sigma Aldrich 
Tris-HCl  >99% Sigma Aldrich 
TRIzol® Reagent - Invitrogen  
Trypan Blue Stain 0.4% Invitrogen  
Trypsin-EDTA 170 000 U 
Trypsin/L 
200 mg/l EDTA 
Lonza 
Tween®20  Sigma Aldrich 
UltraPure™ Agarose - Invitrogen 
Urea  >99.0 % Duchefa BioChemicals 
Xylene Cyanol - Sigma Aldrich 
1s=solid 
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2.16 Equipment and instruments 
Type Manufacturer 
Centrifuges:  
Allegra ™ X-22R Centrifuge Beckman Coultier 
PCR Capsulefuge PMC-860 Tomy 
Spectrafuge mini  Labnet 
Spectrafuge maxi Hitachi 
Avanti™ J-25 Centrifuge Beckman 
Megafuge Heraeus  
Biofuge Fresco Heraeus  
Spectrophotometer:  
UV- visible spectrophotometer UV-160 I Shimadzu 
NanoDrop ND-1000 Saveen Werner 
Incubator:  
Innova 400 incubator shaker New Brunswic scientific 
Innova 4300 incubator shaker New Brunswic scientific 
Termaks incubator Termaks 
Forma Steri-cycle CO2 Thermo scientific 
Waterbath  KeboLab AS 
Gel electrophoresis:  
Electrophoresis power supply EPS 60 Amersham pharmacia biotech 
Electrphoresis power supply ECPS 3000/150s Amersham pharmacia biotech 
Electrophoresis unit: Hoefer He33 Amersham pharmacia biotech 
Hoefer™ SQ3 Sequencer Amersham pharmacia biotech 
PCR:  
PTC-200 Peltier Thermal Cycler MJ research 
StepOnePlus Real-time PCR Applied biosystems 
Sterile hood  
Holten Lamin air Holten 
Diverse:  
3 MM Chromotography paper Whatman® 
BioRad Molecular Imager PhosphorImager  BioRad  
CountessTM Automated Cell Counter Invitrogen  
Glass plate set for s2001/s2 (sequencing gel) AH diagnostics/biometra 
Heat block: QBT1 Grant 
Multiple well Plate, MicroTest™ 96-well Tissue culture Becton Dickinson Labware 
Multiple well Plate, MicroTest™ 24-well Tissue culture Becton Dickinson Labware 
Multiple well Plate, MicroTest™ 6-well Tissue culture Becton Dickinson Labware 
Nitrogen tank: Cryo biological storage system Thermolyne 
Novex® Semi-Dry Blotter Invitrogen  
Nunclon™ 75 cm2 Treated flask, blue filter cap Thermo scientific 
NuPAGE
®
10 % Bis-Tris gel Invitrogen 
Phosphor screen  Amersham Biosciences 
Polyvinylidene difluoride (PVDF) (pore size 0,45 µm) Amersham Biosciences 
Shaker: Edmund Buhler  Hechingen 
Sonicator: LabSonic™ M Sartorius Stedim Biotech 
Typhoon 940 Variable Mode PhosphorImager Amersham Biosciences 
Weighing scale: AT261 Delta Range Mettler Toledo 
Weighing scale: BP 4100 Sartorius 
Vacuum  dryer: Maxi dry Iyo,  Medinor 
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3 Methods 
If not stated otherwise, enzymes, DNA and protein extracts were kept on ice during the 
experiments. DNA and proteins were stored at -20 ˚C and -70 ˚C, respectively. Recipes of 
solutions are listed in Appendix A. 
3.1 Protein purification of NTH1 
NTH1 was expressed and purified for biochemical activity assays. Protein expression can 
be achieved by cloning the gene of interest into a suitable plasmid expression vector, and 
transforming it into a host, such as an E. coli strain. Cell cultures are then grown and 
proteins are purified after induced expression. Protein purification was performed using 
nickel-nitrilotriacetic (Ni-NTA) agarose coloumn. This method is based on affinity 
purification of recombinant proteins tagged with six tandem histidine residues (6xHis-
Tag) at the C- or N-terminal. The protein of interest will bind to Ni-NTA resin with its 
6xHis-Tag, while other proteins pass through the column. Proteins bound to the resin are 
then eluted with a suitable buffer containing imidazole in excess that competes with the 
6xHis-Tag for binding to the Ni-NTA (QIAGEN®, 2003). Purification of NTH1 can be 
performed using this method (Aspinwall et al., 1997).  
3.1.1 Expression of NTH1 
The full-length NTH1 cDNA (Luna et al., 2000) was cloned in into pET28b vector. This 
NTH1/pET28b construct with a C-terminal 6xHis-Tag, transformed into E. coli BL21 
Codon Plus RIL strain, was a gift from Professor Lars Eide, Department of Medical 
Biochemistry, Rikshospitalet. 
Procedure: 
1. The cells were streaked out on Luria-Bertani (LB)-kanamycin (50 µg/ml) medium 
plates and incubated at 37˚C over night (ON).  
2. ON culture was made by inoculating transformants in 20 ml LB-medium 
containing 50 µg/ml kanamycin. The ON culture was incubated at 37 ˚C ON with 
vigorous shaking.  
3. 10 ml of ON culture was transferred to 1 l LB-sorbitol medium and incubated 
with shaking at 37 ˚C until OD600 reached ~0.6.  
4. The protein expression was induced by adding 1 ml IPTG to a final concentration 
of 1 mM, and the cells were further grown at 37 ˚C for 4 h.  
5. Cells were harvested by centrifugation at 6,000 rpm for 5 min at 4 ˚C and 
resuspended in 15 ml buffer A per liter cell culture.  
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3.1.2 Protein purification 
Procedure: 
1. Sonication: 
The cell suspension was sonicated on ice for 3x30 seconds at 60% amplitude, 
with a 30 second cooling period between each burst. 
2. The cell suspension was centrifuged at 13,000 rpm for 20 min at 4 ˚C to pellet the 
cellular debris, and the supernatant was transferred to a fresh tube and kept on ice. 
3. Pre-equilibration: 
A 20 ml purification column was packed with 2 ml of Ni-NTA agarose that 
consists of 50 % ethanol and 50% Ni-NTA. The resin was settled by gravity, and 
pre-equilibrated with 6 ml buffer A that resuspended the resin. The resin was 
allowed to settle for 5-10 min using gravity. 
4. Purification on Ni-NTA column: 
The supernatant, containing protein of interest was loaded on the column and 
incubated for 30 min at 4 ˚C under shaking to keep the resin and supernatant 
suspended. 
5. The resin was then settled by gravity, allowing the supernantant to flow through 
the column. The flow-through (FT) was saved at 4 ˚C for gel analysis.  
6. Wash: 
The column was washed twice with buffer A and B using 3x column volume and 
the wash fractions were stored at 4 ˚C for electrophoresis analysis.  
7. Elution: 
Bound proteins were eluted with 3x column volume of buffer C and collected in 
fractions of 1 ml. The purified protein fractions were analyzed by gel analysis, 
and aliquoted into 30 µl fractions with 20% glycerol for storage at -70 ˚C. Protein 
concentrations were determined using BioRad Protein Assay with BSA as 
standard.     
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3.1.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein gel electrophoresis is a method used to separate proteins according to their size, 
where the smaller proteins migrate faster through the gel than the larger proteins. Since 
proteins neither have a uniform negative charge nor a uniform secondary structure, the 
strong ionic detergent SDS is added in the polyacrylamid gel. The proteins are denatured 
by heating, applied to the SDS-containing gel and subjected to an electrical field. The 
binding of negatively charged SDS to the denatured proteins provides an equal mass to 
charge ratio upon which proteins are separated. The mass of the protein can be 
determined by comparing the protein movements to molecular markers with known 
migration patterns (Watson et al., 2004). 
 
Procedure: 
1. FT, wash fractions and the eluted protein fractions were prepared for gel 
electrophoresis as follows: 
 
Fraction      5.0 µl 
NuPAGE® LDS Sample Buffer (4x) 4.0 µl 
DTT (1 M)     1.0 µl 
MQ     5.0 µl 
Total                          10.0 µl 
  
2. Samples were incubated at 95 ˚C for 3 min and loaded at 10% NuPAGE® Bis-
Tris gel in 1xNuPAGE® MOPS buffer. 
3. 5 µl SeeBlue® Plus2 Prestained Standard was used as a molecular marker. The 
gel ran at 200 V for 35 min.  
4. After the electrophoresis, the gel was stained and destained for 1-2 h by 
Coomassie Blue staining solution and destaining solution, respectively. 
5. The gel was dried under vacuum on Whatman 3MM paper at 80 ˚C for 45 
min.  
  
  3 Methods 
 
31 
 
3.2 Culturing and maintaining cell cultures.  
A cells culture is a major tool used in molecular and cell biology that represent the 
biological model system of the intended experiment. Normal mammalian cells stop 
dividing after a limited number of cell division, and lose their ability to proliferate. 
However, some mammalian cells that have undergone transformations either 
spontaneously, chemically or virally can proliferate indefinitely (Alberts et al., 2008). 
Thus, such immortals cells are often used in biological studies to achieve successful 
transfection and gene knockdown.  
 
Human epithelial cervical carcinoma (HeLa) cells are cancer cells and the oldest 
permanent human cell line. Human immortalized keratinocytes (HaCaT) and HeLa cells 
are described as immortal since they can divide an unlimited number of times in a cell 
culture as long as fundamental growth conditions are present (Lucey et al., 2009). These 
cells are adherent, meaning that they can grow as a monolayer on an artificial substrate 
that is suitable for cell adhesion and spreading.  
 
Sterile and aspetic work area is required when working with different cell lines.  All 
incubations were performed in a humified atmosphere at 37 ˚C with 5.5% CO2.  Cells 
were regularly passaged and monitored in microscope to maintain exponential growth and 
determine cell confluency. Dulbeccos’s Modified Eagle medium (DMEM) containing 4.5 
g/l glucose, 10% fetal bovine serum (FBS), 2% L-glutamine and 2% penicillin-
streptomycin, is further referred as culture medium. Phosphate buffered saline (PBS), 
culture medium, and trypsin, otherwise kept at 4˚C, should be room tempered when added 
to the cells. Detailed guidelines and and procedures are refered in (Invitrogen®, 2012). 
  
  3 Methods 
 
32 
 
3.2.1 Initiating cell culture from a freezing stock 
Procedure: 
1. The cell culture was initiated from common frozen seeding stock, by immediately 
thawing the cells at 37 ˚C water bath and mixing the contents gently with 10 ml 
culture medium.  The solution was then centrifuged at 1,200 rpm for 3 min.  
2. The pellet was resuspended in 1 ml culture medium and mixed gently by pipetting 
up and down. 
3. The cell suspension was transferred to a Nunclon™ 75 cm2 (T75)-flask and 
diluted with culture medium up to 15 ml. The cells were examined on the 
microscope and incubated at 37 °C for 2-4 days until cell confluency reached 70-
80%. 
3.2.2 Passaging cells 
Procedure: 
1. When cell confluency reached 70-80%, the culture medium was removed. Since 
only the adherent cell lines were used, the cells remained stuck to the flask 
bottom.  
2. The cells were gently washed with 1xPBS to remove residual medium. 
3. 2 ml Trypsin-EDTA, just enough to cover the cell surface, was added to the T75-
flask and incubated for 5 min to detach the cells.  
4. Trypsin was then inactivated by trypsin inhibitors found in FBS, by adding 8 ml 
culture medium, which was vigorously pipetted up and down to detach all cells. 
Detached cells were observed under the microscope. 
5. The cell suspension was then transferred to a fresh tube and centrifuged at 1,200 
rpm for 3 min to remove trypsin and EDTA.  
6. The pellet was resuspended in 1 ml culture medium. 
7. Counting of viable cells are not necessary when passaging cell cultures, however 
this additional step is required to determine the seeding density in dishes before 
transfection. 10 µl of the cell suspension was added to 10 µl 0.4% Trypan Blue 
Stain. Amount of cells in a cell culture was then determined by using CountessTM 
Automated Cell Counter” according to the manufacturer’s instructions.  
8. The cells suspension was split in 1:10, 1:5 or 1:4 fractions and diluted with 
culture medium up to 15 ml in a T75-flask every 2-5 days depending on the 
confluency. The cell cultures were incubated at 37 ˚C. 
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3.2.3 Preparation of frozen seeding stocks 
Procedure: 
1. To prepare freezing stocks for storage and future use, step 1-5 in section 3.2.1 was 
followed. 
2. The pellet was resuspended in 1 ml prepared cryo medium containing 10% 
dimetylsulfoxide (DMSO) that reduces the freezing point of the medium and 
prevents the formation of ice crystals that could cause damaged cells or cell death. 
The cryovial was stored at -70 ˚C for few days before transferring the vial to 
liquid nitrogen tank at –130 ˚C for long time storage.  
3.2.4 Detecting contamination in cell lines 
Cell health is essential to achieve successful experiments, however contaminated cells 
represent a major problem when working with biological material since they may alter 
cellular characteristics. For example mycoplasma, a simple bacteria that is considered to 
be the smallest self-replicating organism, is difficult to detect until they reach extremely 
high frequency (Invitrogen®, 2012;van Kuppeveld et al., 1994).  
 
To check for mycoplasma contamination in cell cultures PromoKine’s PCR mycoplasma 
Test Kit II- protocol, designed for detecting mycoplasma in biological materials was 
followed (Appendix B).  
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3.3 Transfection of cells with siRNA and gene knockdown 
Transfection is the process used to deliver foreign nucleic acid into mammalian cells that 
can be used to down-regulate the gene of interest. One technique used to transfect cells, 
rely on cationic liposomes that interact with the 
negatively charged foreign nucleic acid, 
resulting in liposome-nucleic acid complexes. 
This complex will get transfected into the cell 
by endocytosis and release the foreign nucleic 
acid. When small interfering RNA (siRNA) are 
used to transfect the cells, they are released in 
the cytoplasma, where they become a part of the 
RNA-induced silencing complex (RISC) and 
denatured (Figure 3.1) (Felgner et al., 1987). 
The presence of ss siRNA will direct the 
complex to a complementary messenger RNA 
(mRNA), resulting in inhibition of translation 
and degradation of that specific mRNA (Watson 
et al., 2004). 
 
Another aspect to consider is whether the transfection should be transient or stable. Stable 
transfection ensures that foreign DNA is integrated in the genome permanently. Transient 
transfections on the other hand requires less time, however the effect is only temporary 
(Felgner et al., 1987;Sambrook and Russel, 2001).  
 
To achieve down-regulation of NTH1 and TDP1 in mammalian cells, different cell lines 
were transiently transfected with siRNA specific to NTHL1 and TDP1 genes using 
cationic liposomes to transfect cells. Additional cells were also transfected with non-
targeting control siRNA, designed as a negative control.  
 
3.3.1 Optimizing transfection conditions and evaluating knockdown 
Procedure: 
1. To determine when the highest transfection efficiencies were achieved, different 
transfection conditions were optimized using varying combinations of siRNA and 
LipofectamineTM RNAiMAX Reagent. 
Figure 3.1. Schematic illustration of 
transfection of siRNA and its assembly 
in RISC (Li and Rana, 2012).  
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2. 4x104 cells/well were seeded in a 24-well plate in a total volume of 500 µl culture 
medium without antibiotics.  
3. When indicated, 0, 1.2, 6 and 30 pmol siRNA was transfected in combination 
with 0.5, 1.0 and 1.5 µl LipofectamineTM RNAiMAX in a total volume of 100 µl 
DMEM. All combinations were replicated twice.  
4. The cells were transfected at 50-70% confluency as described in “Forward 
Transfection Protocol” from Invitrogen (Appendix C). 
5. Cells were washed and harvested 48 h after transfection by 100 µl 1xPBS and 50 
µl protein-cracking buffer, respectively. The samples were sonicated using a 
microtip for 3x20 second, at 30% amplitude under 0.6 seconds cycles.  
6. The samples were incubated at 95˚C for 3 min and centrifuged at 13,000 rpm for 
5 min.  
7. Since protein concentrations could not be measured, 25 µl of the sample were 
loaded onto a 10% NuPAGE® Bis-Tris gel for Western Blot analysis, described in 
section 3.4.1, to evaluate down-regulation of NTH1 and TDP1. 
8. The proteins were separated at 170 V for 60 min and 3 µl µl MagicMark™ XP 
Western Protein Standard was used as a molecular marker. 
 
3.3.2 Transient Transfection assay 
The various amounts of LipofectamineTM RNAiMAX, siRNA and medium used are in 
proportion to the relative surface area of the culture plates used (Appendix C). Thus, the 
amounts of concentrations and cell densities used in a 6-well plate corresponds to 4x104 
cells/well, 1.2 pmol siRNA and 1.5 µl LipofectamineTM RNAiMAX used in the 24-well 
plate in section 3.3.1. 
 
Procedure 
1. Different cell lines were seeded in 6-well plates at a density of 2x105 cells/well 
using a total volume of 2.5 ml culture medium without antibiotics. The cells were 
incubated at 37 ˚C until confluency reached 50-60%. 
2. Cells were transfected by adding 7.5 µl LipofectamineTM RNAiMAX Reagent and 
6 pmol of NTHL1-siRNA or TDP1-siRNA in a total volume of 500 µl DMEM. 
Additional cells were also transfected with control siRNA in the same manner, 
using the same amount of control siRNA. Each transfection was replicated twice. 
3. The cells were incubated for 48 h and further assayed for gene knockdown. 
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3.3.3 Preparation of whole-cell protein extracts  
Procedure: 
1. Transfected cells were washed in 500 µl 1xPBS, harvested by trypsinization using 
500 µl Trypsin-EDTA and incubated for 2-3 min.  
2. 1 ml of culture medium was subsequently added, mixed gently and the cell 
suspension from each well was transferred to a microcentrifuge tube, which was 
then centrifuged at 13,000 rpm for 2 min. 
3. The pellets were washed once in 1xPBS and resuspended in 1 ml lysis buffer on 
ice.  
4. The samples were incubated on ice for 15 min, sonicated for 2x30 second at 30% 
amplitude under 0.6 seconds cycles and centrifuged at 13,000 rpm for 15 min.  
5. The supernatant containing proteins was transferred to a fresh microcentrifuge 
tube and kept one ice.  
6. Total protein concentrations were determined by BioRad Protein Assay.  
7. 25 µg proteins were loaded onto a 10% NuPAGE® Bis-Tris gel in a total volume 
of 25 µl containing 1x LDS Sample buffer and 100 mM DTT.  
8. 3 µl MagicMark™ XP Western Protein Standard was used as a molecular marker. 
9. The proteins were separated by electrophoresis for 60 min at 170 V and the gel 
was further used in Western blot analysis. 
 
3.4 Evaluation of gene knockdown  
To determine the success of gene knockdown by transfecting siRNA into cell lines, 
Western blot and real time-polymerase chain reaction (RT-PCR) can be performed. 
3.4.1 Western blotting 
Western blotting is a method used to transfer electrophoretically separated proteins to a 
membrane by applying an electric field through the gel that is in direct contact with the 
membrane. Once the proteins are transferred, the non-specific binding sites are blocked 
by incubating the membrane in a blocking buffer containing proteins unrelated to the 
protein of interest. The membrane is then incubated in a solution of a primary antibody 
that specifically recognizes and can only bind to the target protein. A chromogenic 
enzyme that is artificially attached to a second antibody that binds the primary antibody is 
used to visualize the target protein (Watson et al., 2004).  
  
  3 Methods 
 
37 
 
Procedure: 
1. The electrophoretically separated proteins were transferred to a polyvinylidene 
difluoride (PVDF) membrane using Novex® Semi-Dry Blotter at 20 V for 30 min 
(Appendix D).  
Post-transfer: 
2. The membrane was washed in 1xPBS for 2 min and subsequently blocked in 
PBS-Tween buffer containing 5% skim-milk, on a shaker for 1 h in room 
temperature (RT) or ON at 4 ˚C. 
3. PBS-Tween buffer was used to wash the membrane 3x5 min on a shaker. 
4. The membrane was incubated with primary antibody in PBS-Tween buffer 
containing 3% skim-milk buffer ON at 4 ˚C or 1-3 h at RT. Different antibodies 
required different dilutions as listed in section 2.4. 
5. The membrane was washed in PBS-Tween buffer for 5x10 min in RT under 
strong agitation. 
6. 1:30,000 dilution of a horseradish peroxidase (HRP)-conjugated secondary 
antibody, was added and the membrane incubated for 1 h on a shaker at RT.   
7. PBS-Tween buffer was used to wash the membrane 6x10 min under strong 
agitation. 
8. Immun-Star™ WesternC™ Kit from BioRad was used according to the 
manufacturer’s instructions, and the membrane was immediately visualized in 
BioRad Molecular Imager.  
Antibodies can be removed from the membrane by stripping when detection of more than 
one protein on the same membrane is wanted. This was performed by removing primary 
and secondary antibodies from the membrane and re-incubating with an antibody specific 
for a protein that is expected to occur in equal amounts, thereby acting as a loading 
control.  
Procedure: 
9. Stripping-buffer containing β-mercaptoethanol was pre-heated to 50 °C and added 
to the membrane, which was then incubated for 45 min at 50 °C with some 
agitation. 
10. Traces of β-mercaptoethanol can damage the antibodies. Thus, the membrane was 
washed extensively with MQ under strong agitation for 1-2 h, before repeating 
step 1-8 and using Anti β-Actin antibody as the primary antibody. 
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3.4.2 RT-PCR 
RT-PCR is a technique based on PCR, a method that amplifies segments of DNA up to 
few thousand base pair. PCR is a cyclic process and can be summarized in three steps; 
denaturation of the original DNA, annealing of primers to the DNA template strand and 
polymerization by DNA polymerases. However, standard PCR have its limitations since 
the product is only detected at the end of the reaction on an agarose gel. In RT-PCR on 
the other hand, the products can be measured continuously and during the exponential 
phase of the reaction providing accurate and fast quantification of DNA and RNA levels 
in cells.  
 
For quantification of mRNA, RT-PCR is often combined with reverse transcription that 
yields a complementary DNA (cDNA) copy from the total isolated RNA. Gene 
expression for a target gene can then be detected by using RT-PCR to amplify the cDNA. 
Detection is obtained by adding fluorescent probes, such as SYBR Green that will bind 
non-specifically to the minor grove of ds DNA, resulting in increased intensity of 
fluorescence. As the ds DNA is amplified, the level of fluorescence increases 
proportionally, making it possible to accurately determine the precise amount of target 
mRNA present in the cells (Valasek and Repa, 2005). 
 
Isolation of RNA from transfected cells  
Procedure: 
1. HeLa S3 cells transfected with siRNA specific to NTHL1 were harvested 48 h 
after transfection by trypsinization and centrifugation, as described in step 1-2 in 
section 3.3.3. 
2. Each pellet was resuspended in 750 µl TRIzol® Reagent to homogenize the 
samples and incubated at RT for 5 min. 
3. 150 µl chloroform was added and the tube was shaken vigorously for 15 seconds. 
4. The samples were incubated for 2-3 min at RT, and then centrifuged at 12,000 
rpm for 15 min at 4 °C, which resulted in a colorless upper aqueous phase, an 
interphase and a lower red phenol-chloroform phase. 
5. The aqueous phase, containing RNA, was transferred to a fresh tube. 
6. 375 µl 100% isopropanol was added to the aqueous phase, incubated at RT for 10 
min and centrifuged at 12,000 rpm for 10 min at 4 °C. 
7. The pellet, containing RNA, was washed in 750 µl 75% ethanol, before 
centrifuging the tube at 7,500 rpm for 5 min at 4 °C. 
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8. The supernatant was discarded and the pellet was air-dried for 15 min. 
9. The RNA pellet was resuspended in 30 µl RNAse free water and incubated at 55 
°C for 10 min.  
10. 3.3 µl 10xTURBO™ DNase buffer and 0.5 µl TURBO™ DNase was added to 
remove any remaining residual DNA. 
11. The samples were incubated at 37˚C for 30 min and reaction was subsequently 
stopped at 75˚C for 10 min.  
12. Concentration of RNA was measured using NanoDrop® ND-100. 
 
cDNA synthesis 
Procedure: 
1. 1 µg of the total RNA from each sample was used for cDNA synthesis. The 
samples were prepared by using “High Capacity RNA-to-cDNA Kit” from 
Applied Biosystems as instructed by the manufacturer’s protocol (Appendix E). 
2. The samples were incubated in a thermal cycler at 25˚C for 10 min, subsequently 
followed by 37˚C for 2 h. The reactions were then stopped by raising the 
temperature to 85˚C for 5 seconds and the samples were subsequently held at 
10˚C. 
3. The remaining RNA samples were stored at -70 ˚C. 
 
Preparing standard curves to determine the amount of cDNA to use  
The cytoskeletal protein β-Actin, encoded by the gene ACTB, was used as the 
housekeeping gene for normalization. To determine the amplification efficiencies of the 
target gene, primers specific for target gene and β-Actin were used to generate standard 
curves.   
Procedure: 
1. Two standard curves of 5 points were generated by making five standard 
solutions with 1:5 dilutions of cDNA prepared from control cells transfected 
with non-targeting siRNA. 
2. Triplicates were made of each standard solution. 
3. To generate each standard curve, primers for the target gene; NTHL1 and 
ACTB were used. Primers are listed in section 2.5. For sequence information 
of NTHL1 gene, see GeneBank: National Center for Biotechnology 
Information (NCBI), accession number NM_002528.5. 
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4. Following reaction mixture was prepared for each of the primerpairs. 
 
1:5 serial dilution of control cDNA  1.0 µl 
Forward primer (100 nM)    0.2 µl 
Revers primer (100 nM)    0.2 µl 
Power SYBR® Green PCR master mix  8.0 µl 
MQ                            10.6 µl 
Total                          20.0 µl 
 
5. RT-PCR was performed using program: Comparative method of relative 
quantification in StepOne™ v2.1 Software, provided by Applied Biosystems.  
 
Assaying gene knockdown in RT-PCR 
Procedure: 
1:10 dilutions of control cDNA samples and cDNA samples obtained from cells 
transfected with NTHL1-siRNA were prepared in triplicates, using primerpairs specific to 
the ACTB and NTHL1 as previously described in step 4-5 above. 
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3.5 Biochemical activity assays 
To investigate the activity of an enzyme of interest 
on a specific damage, biochemical activity assay 
can be performed. This is achieved by radioactively 
labeling the DNA substrate, containing base 
damage of interest, on the 5’-end with [γ-
32P]adenosine triphosphate (ATP) and T4 
polynucleotide. The DNA substrate can also be 
labeled at the 3’-end with [α-32P]deoxyATP 
(dATP) (Tu and Cohen, 1980). The principle is 
based on radioactively labeling the DNA substrate 
only one end, so the location of any break in the 
strand can be determined by the size of the 
resulting labeled substrate (Figure 3.2). To stop the 
enzymatic reactions on the radioactively labeled 
DNA substrate, a formamide loading dye is added 
that denaturates the DNA. The DNA products can 
then be separated on a denaturing polyacrylamide 
gel (Alberts et al., 2008). The radioactive DNA 
products are typically visualized and quantified by 
phosphorimaging by exposing the gel to a phosphor 
screen. When the screen is scanned by a laser, it will emit light in proportion to the 
amount of radioactivity in the samples (Amersham Biosciences®, 2012).  
3.5.1 Activity assays performed on [
32
P]-5’-labeled DNA substrates  
Purified enzymes like S. pombe Tdp1, E. coli Nth, human APE1 and NEIL1, used as 
controls, were provided from common stocks in the laboratory and diluted in dilution 
buffer as indicated. Ss and ds DNA substrates containing single base damages were 
radioactively labeled at 5’end or 3’end as described in (Nilsen et al., 2012) by Alseth and 
Erik Sebastian Vik. 
 
Whole-cell protein extracts of heart, liver and brain from five wild-type (WT) mice, six 
Neil1 single KO (S-KO) mice, six Neil2 S-KO mice and six Neil1/Neil2 double KO (D-
KO) mice were prepared as described in (Yndestad et al., 2009), and were a gift from 
Susanne Vetlesen. Serial dilutions of the whole-cell protein extracts were made by using 
Figure 3.2. Simplified schematic presentation of 
5'end-labeled  activity assay. 
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Tris-sucrose/MOPS buffer. The sequences of DNA substrates used in these studies are 
listed in section 2.9. 
Procedure: 
1. 10 µl of a reaction mixture was prepared by mixing following components: 
 
Enzyme1     1.0 µl 
DNA substrate (10 fmol)  1.0 µl 
5xReaction buffer   2.0 µl 
MQ    6.0 µl 
Total               10.0 µl 
 
2. The reaction samples were incubated at 37 ˚C for 30 min. 
3. The reactions were stopped by adding equal volume of formamide loading dye in 
volume ratio. 
4. The samples were denatured at 90 ˚C for 3 min. 
5. The reactions products were separated on a 20% polyacrylamid gel at 200 V for 1 
h in 1xTaurine buffer, by applying 4 µl of the reaction sample. To achieve single 
nucleotide resolution, the DNA products were also separated on 20% sequencing 
gel at 40 W for 2.5 h using Hoefer™ SQ3 Sequencer.  
6. The gel was dried under vacuum for 45 min at 80 ˚C and exposed to 
phosphoscreen ON. 
7. The radiolabeled products were visualized by using Typhoon PhosphorImager 
and ImageQuant TL software was used for quantification.  
8. The remaining samples were stored at -20 ˚C.  
9. When intact AP sites were processed 1 µl 50 ng/µl Proteinase K and 1 µl 5% SDS 
was also included in the reaction mixture after the incubation step, followed by 
additional incubation at 65 ˚C for 15 min. This was done to improve the detection 
of the cleaved DNA substrate since Proteinase K degrades redundant proteins in 
the native state. 
10. When indicated:  
¾ 1 µl of 0.5 M NaOH was added after the incubation step to hydrolyze 
uncleaved AP sites and the incubation continued for additional 10 min at 
70 ˚C, followed by neutralization with 1 µl 0.5 M HCl. 
                                                          
1
 Purified recombinant proteins or whole-cell extracts from WT and KO mice or HeLa S3 cells. 
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¾ Different amount of inhibitors like myricetin and sodium orthovanadate 
were included in the reaction mixtures, notably before the enzymes were 
added to the DNA substrates. 5xTDP1 buffer was used instead of 
5xReaction buffer for optimal TDP1 activity. 
3.5.2 Preparation of AP site using [
32
P]-5’-labeled DNA substrates 
Procedure: 
1. DNA substrates with an intact AP site were produced by pre-treating the uracil-
containing ss and ds 40-mer DNA substrate Uracil DNA glycosylase (Udg) as 
described below: 
 
5xReaction buffer   0.25 µl 
Udg (5,000 U/ml)   0.05 U 
DNA substrate (10 fmol)  1.00 µl 
Total    1.25µl 
 
2. When indicated, 0.1 U E .coli Nth (10,000 U/ml) was also included to generate a 
nicked AP site with a 3’dRP terminus. 
3. The mixture was incubated at 37 ˚C for 30 min, subsequently followed by 
additional incubation at 55 ˚C for 10 min.  
4. 1 µl of the Udg-treated DNA substrate was added to each sample of reaction 
mixture. The reaction mixtures are prepared and separated on gel as described 
previously through step 1-8 in section 3.5.1.  
3.5.3 Sodium borohydride-mediated trapping assay 
A 32P-5’end-labeled ds DNA substrate containing 5-OHU opposite G was used in 
trapping assay. 
 
Procedure: 
1. 10 µl of reaction mixtures were prepared as described in step 1 in section 3.5.1 
with 1 µl of 1 M sodium borohydride. 
2. The samples were incubated at 37 ˚C for 30 min, and the reaction were stopped 
by adding 2.5 µl 4xNuPAGE® LDS Sample buffer and 1 µl 1 M DTT. 
3. The samples were denatured at 95 ˚C for 3 min. 
4. 5 µl of the samples were applied and separated on 10% NuPAGE® Bis-Tris gel at 
150 V for 1 h. Step 6-8 in section 3.5.1 was further followed to visualize the gel.  
Multiplied with the number 
of total reaction samples 
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3.5.4 Activity assays perfomed on [
32
P]-3’-labeled DNA substrates  
The enzyme activities were investigated using 32P-3’end-labeled 24-mer ds DNA 
substrate. The reaction products were separated on 20% sequencing gel at 45 W for 3-4 h 
in 1xTBE buffer. 
Procedure: 
1. Intact AP site opposite C on the 14th position from the 5’end was produced by 
pre-treating the DNA substrate with Udg as described in section 3.5.2. 
2. When indicated: 
¾ 2 mM MgCl2 was added in reaction samples, before incubating them at 
37 ˚C for 30 min. 
¾ AP site was nicked by adding 4 ng APE1 subsequent to E. coli Udg 
addition, and incubated for additional 30 min at 37 ˚C. 
3. The samples, after incubation, are added 2 µl of the reducing agent sodium 
borohydride. 
4. For effective precipitation of DNA products are following reagents added and the 
samples are briefly centrifuged between each addition.  
 
¾ tRNA  (1 µg/µl)       1.0 µl 
¾ sodium acetat (3 M, pH 5.5)    1.3 µl 
¾ 96% ethanol                 30.0 µl  
 
5. The samples were mixed thoroughly and incubated at -20 ˚C for 30 min, before 
centrifuging them at 13,000 rpm for 30 min at 4 ˚C to pellet the DNA products. 
6. 30 µl of 70% ethanol was used to wash the pellet and the samples were 
centrifuged for 5-10 min. 
7. The pellet was air-dried for 10-15 min and resuspended in 10 µl formamide 
loading dye. The samples were denatured at 75 ˚C for 2 min.  
8. 3 µl of the samples were applied on the 20% sequencing gel and separated using 
Hoefer™ SQ3 Sequencer. 
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4 Results  
Mutagenic and cytotoxic AP sites are amongst the most frequently formed lesions in 
DNA. To gain better understanding of how AP sites are processed and repaired in 
mammalian cells, recombinant NTH1, KO mice models and immortalized human cell 
lines have been used. 
4.1 Purification of recombinant NTH1 using Ni-NTA column 
The protein NTH1, expressed in E. coli BL21 Codon Plus RIL strain using 
NTH1/pET28b construct, was purified using Ni-NTA column. 5 µl of protein fractions 
were separated on 10% NuPAGE® Bis-Tris gel, and an induction of a protein of ~39 kDa 
was observed that corresponded to the expected size of NTH1 (Figure 4.1). Engineers in 
the laboratory had earlier analyzed the expressed protein isolated from NTH1/pET28b 
construct by mass spectroscopy. Thus, no further purification or analysis was necessary. 
Consistent with the presence of an iron-sulfur cluster within NTH1, the purified protein 
had a yellow coloration. FT and wash fractions showed no substantial loss of protein of 
interest during purification. The eluted protein fraction in lane 3 was used in further 
experiments. The protein concentration was determined to 930 ng/µl by BioRad Protein 
Assay using BSA as a reference. 
 
Figure 4.1. Detection of recombinant NTH1 protein after IPTG induction by SDS-PAGE using 
10% NuPAGE
® 
Bis-Tris gel and Coomassie Blue staining. The red arrow indicates the presence 
of NTH1 at ~39 kDa. SeeBlue
® 
 Plus2 Prestained Standard (1x) was used as a molecular marker. 
The purified protein NTH1 was eluted from Ni-NTA column in six fractions using 300 mM 
imidazol. Flow-through was collected and the two wash fractions were derived from washing the 
Ni-NTA column with 10 mM and 30 mM imidazol, respectively. 
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4.2 Cleaving activity of NTH1 
Recombinant NTH1 was used in biochemical activity assays to gain better understanding 
of its DNA cleaving activity upon various DNA damages. 
4.2.1 Processing of 5-OHC by NTH1 
The activity of purified NTH1 was measured using a 5’end-labeled DNA substrate 
containing 5-OHC, which is a known substrate for NTH1. When indicated, 0.5 M NaOH 
that hydrolyzes AP sites, was also added to determine whether the glycosylase or AP 
lyase activity is coupled.  
Cleaving activity was observed in both 40-mer ss and ds DNA substrate containing 5-
OHC, although the ss DNA substrate was cleaved less efficiently. Indeed, the ds DNA 
substrate was cleaved approximately twice as efficiently as the ss DNA substrate (Figure 
4.2).  
Figure 4.2. The activity of NTH1 upon 
32
P-5’end-labeled 40-mer DNA substrate containing 5-
OHC. (A) Different amounts of NTH1 are indicated and were incubated with ss and ds DNA 
substrate containing 5-OHC (10 fmol) for 30 min at 37 °C. Cleaved DNA substrates were 
separated from intact DNA substrates by 20% denaturing PAGE and visualized by 
phosphorimaging. Purified NEIL1 (10 ng) was used as control for 3’OH terminus.  Experiments 
were repeated twice, one representative experiment is shown. (B) Cleaved substrate (%) was 
plotted against different amounts of NTH1 (2.5, 10 and 20 ng). The cleavage products were 
quantified using ImageQuant TL and the background was subtracted during quantification. “+” 
and “-“ denotes reactions with and without 0.5 M NaOH, respectively.  
 
 
Only ~10% increase in cleaved substrate was observed when NaOH was added to the 
reaction, which represents the fraction of bases that are removed without any subsequent 
AP lyase incision. Thus, most of the activity of NTH1 seems to be coupled, meaning that 
if NTH1 removes the damaged base, a subsequent incision 3’ to the AP site will follow in 
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most cases, at least when NTH1 is the only enzyme acting upon the damaged substrate. 
However, as the results indicate, in ~10% of the cases, NTH1 will act only as a 
monofunctional DNA glycosylase.  
4.2.2 Processing of AP sites using recombinant NTH1 
A 5’end-labeled ss DNA substrate containing an AP site on the 15th position from the 
5’end was used to investigate in what extent the recombinant NTH1 is able to incise AP 
sites. AP site opposite A, C, T or G was used to determine whether the activity of NTH1 
was affected by the opposite base. 
A 15-mer product was generated when NTH1 nicked 3’ to the AP site, producing a 3’dRP 
terminus. The different bases opposite the AP site did not affect the rate of incision. 20 ng 
NTH1 was able to cleave ~60% of the ds DNA substrate, but only ~15% of ss DNA 
substrate, demonstrating that ds DNA are better substrates than ss DNA for NTH1 (Figure 
4.3).  
 
Figure 4.3. The activity of NTH1 upon 
32
P-5’end-labeled 40-mer DNA substrate containing intact 
AP site opposite G, C, T or A. Cleaved substrate (%) was plotted against different amount of 
NTH1 (2.5, 10 and 20 ng) that were incubated with ss and ds DNA substrate containing (10 fmol) 
for 30 min at 37 °C. Experiments were replicated twice, one representative experiment is shown.  
 
4.2.3 Processing of 5’dRP by recombinant NTH1 
The activity of NTH1 upon a 5’dRP terminus generated by APE1 was also investigated 
by adding serial dilutions of NTH1 to 3’end-labeled DNA substrate containing either 
intact or nicked AP site. The AP site was nicked by APE1 to generate a 5’dRP terminus 
and 2 mM Mg2+ was included for optimal APE1 activity.  
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10 ng NTH1 was sufficient to efficiently cleave the intact AP site to produce 5’P product, 
whereas 100 ng was required to generate corresponding amount of 5’P product from an 
APE1-nicked AP site (Figure 4.4). As 10-fold more enzymes are required to generate the 
corresponding cleavage product from a 5’dRP terminus compared to an intact AP site, 
suggest that 5’dRP is a poor substrate for NTH1.  
Figure 4.4. Processing of 5’dRP terminus and intact AP site opposite C by NTH1 using 
32
P-3’end-
labeled 24-mer DNA substrate. (A) The different amounts of NTH1 used are indicated and were 
incubated with intact or APE1-nicked AP site (10 fmol) for 30 min at 37 °C. Cleaved DNA 
substrates were separated from intact DNA substrates by 20% denaturing PAGE and visualized 
by phosphorimaging. Purified APE1 (10 ng) and E. coli Nth (2 U/µl) were used as positive 
controls for 5’dRP and 5’P termini, respectively. Experiments were repeated twice, one 
representative experiment is shown. (B) Generated 5’P product (%) was plotted against different 
amounts of NTH1 (10, 50 and 100 ng). The cleavage products were quantified using ImageQuant 
TL and the background was subtracted during quantification.  
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4.3 Processing of AP sites in mice 
KO mouse models were used to study the biological role of Neil1, Neil2 and Nth1 in the 
processing of AP sites. Here, various biochemical activity assays were performed on 
whole-cell protein extracts prepared from either liver, heart or brain of six months old 
WT and KO mice. The lack of Neil1 and Neil2 in S-KOs or D-KOs has been established 
by engineers in the laboratory by genotyping and RT-PCR (unpublished material). 
4.3.1 Processing of intact AP sites 
Whole-cell extracts prepared from liver were used to compare the cleaving activity of 
Neil1 S-KO, Neil2 S-KO, Neil1/Neil2 D-KO and WT upon a 5’end-labeled ds DNA 
substrate containing AP site on the 15th position opposite G, T, C or A (Figure 4.5). 
Furthermore, E. coli Nth and NEIL1 were used as markers for β-elimination and β,δ-
elimination product, respectively. One cleavage product was observed when WT, D-KO 
or S-KO were used that migrated between the β-elimination and β,δ-elimination product, 
suggesting that the detected product was generated by the activity of Ape1. In addition, 
processing of AP site opposite A, C, G or T produced similar results, demonstrating that 
the processing occurs independent of the base in the complementary strand.  Thus, only 
one representative substrate is shown, as indicated in each figure. 
 
No statistical significant differences between the cleavage products in neither the S-KO 
and D-KO, nor WT and D-KO (p > 0.1) were observed. These results suggest a non-
essential role of Neil enzymes in AP site strand incision since the lack of either both Neil 
enzymes or just one, do not affect the incision of the AP site substantially compared to 
WT mice (Figure 4.5). Thus, only WT and Neil1/Neil2 D-KO were included in further 
experiments. The statistical significance was determined by performing a statistical T-
test, using a 90% confidence interval. A p value higher than 0.1 was considered to be 
statistical insignificant. The cleavage products were quantified first using ImageQuant TL 
and the background was subtracted during quantification. Five or six parallels from each 
genotype were used to calculate means and standard deviations for the cleaving activity. 
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Figure 4.5. Total product  generated (%) from a 
32
P-5’end-labeled 40-mer DNA substrate 
containing an intact AP site opposite G, was compared for whole-cell liver extracts prepared 
from all four genotypes. AP site opposite other bases showed similar results as well. (A) 1.5 µg 
liver extracts were incubated with DNA substrate containing intact AP site (10 fmol), for 30 min 
at 37 °C. Cleaved DNA substrates were separated from intact DNA substrates by 20% 
denaturing PAGE and visualized by phosphorimaging. Purified E. coli Nth (2 U/µl) and NEIL1 
(10 ng) were used as markers for β-elimination and β,δ-elimination activity, respectively. 
Experiments were repeated twice, one representative experiment is shown. (B)  Means and 
standard deviations were calculated using five or six parallels of each genotype. p values were 
calculated using statistical two-tailed T-test and a 90% confidence interval. The results were 
quantified using ImageQuant TL and the background was subtracted during quantification.   
 
To achieve single nucleotide resolution, DNA products were separated on 20% 
denaturing sequencing gels that made it possible to distinguish between products 
generated by different enzymes. Nth1 incises the 5’end labeled DNA substrate 3’ to the 
AP site, generating a product that migrates slower than the product generated by Ape1. 
Neil1 and Neil2, on the other hand generates the 3’P product through a β,δ-elimination 
step that migrates fastest through the gel, even though it is not the shortest fragment due 
to the negative charge provided by the phosphate group on the 3’end.  
 
The experiments performed on whole-cell extracts from liver, heart and brain, using WT 
and D-KO mice, all demonstrated that intact AP sites are mainly processed by the activity 
of Ape1, as expected (Figure 4.6). The product from Nth1’s activity, 3’dRP, was also 
observed in both WT and D-KO in all three organs, although to a lesser extent than the 
3’OH product generated by Ape1. In addition, within the three organs tested, the AP site 
processing in liver extracts was twice as efficient as compared to heart and brain.  This is 
demonstrated by the fact that 0.5 µg liver extracts were sufficient to process the AP site 
efficiently, whereas 1.8 and 2.0 µg of heart and brain extracts were required to observe 
corresponding processing of AP sites, respectively. 
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Figure 4.6. Processing of intact AP site opposite G using whole-cell extracts from liver, heart and 
brain. (A) Different amounts of extracts that were incubated with a 
32
P-5’end-labeled 40-mer 
DNA substrate containing intact AP site (10 fmol), for 30 min at 37 °C, are indicated in each 
figure. Cleaved DNA substrates were separated from intact DNA substrates by 20% denaturing 
PAGE and visualized by phosphorimaging.  E. coli Nth (2 U/µl), NEIL1 (10 ng) and APE1 (10 ng) 
were used positive controls for 3’dRP, 3’P and 3’OH termini, respectively. Experiments were 
repeated twice, one representative experiment is shown. (B) The charts represent the observed 
3’dRP and 3’OH products in liver, heart and brain when 1.0, 1.8 and 2.0 µg whole-cell extract 
was used, respectively. Blue and red bars denote the activity of generated 3’OH and 3’dRP 
products, respectively. The fraction of 3’dRP and 3’OH product was compared with each other. 
The results were quantified using ImageQuant TL and the background was subtracted during 
quantification. Means and standard deviations were calculated using five or six parallels of each 
genotype. p values were calculated using statistical two-tailed T-test and a 90% confidence 
interval. AP site opposite other bases showed similar results as well. 
 
The high abundance of the 3’OH product compared to the 3’dRP is consistent with the 
fact that Ape1 is mainly responsible for the AP site cleaving activity in mammalian cells 
(Chen et al., 1991). Results also showed no change in 3’dRP product in Neil1/Neil2 D-
KO compared to the WT, indicating no change in the level of Nth1 in the absence of Neil 
enzymes.  
 
To further investigate any up-regulation of Nth1 in the absence of Neil enzymes on a 
quantitative level, Western blot analysis was performed on 20 µg of WT and Neil1/Neil2 
  4 Results  
 
52 
 
D-KO extracts from all three organs. Although several bands of different sizes were 
detected, one band represented the expected size of target protein, as indicated. No up-
regulation of Nth1 was observed in Neil1/Neil2 D-KO extracts compared to WT in any of 
the three organs, suggesting that the amount of Nth1 does not increase noteworthy when 
Neil enzymes are absent (Figure 4.7A). β-Actin was used as loading control, and the gel 
was also stained by Coomassie Blue after blotting to demonstrate equal amounts of WT 
and Neil1/Neil2  D-KO extracts loaded (Figure 4.7B). Different amount of β-Actin was 
observed in brain and liver, whereas β-Actin was not even detected in heart, which was 
unexpected. However, equal amounts of β-Actin were detected within each organ, making 
it possible to compare WT with Neil1/Neil2 D-KO.  
 
 
Figure 4.7. (A) Western blot performed on 20 µg of whole-cell extracts prepared from brain, liver 
and heart, using WT and Neil1/Neil2 D-KO mice. Endogenous NTH1 was detected using 1:500 
dilution of Anti-NTH1 antibody. MagicMark™ XP was used as Western protein standard. β-
Actin was used as loading control and detected with 1:2,000 dilution of Anti-β Actin antibody. (B) 
10% NuPAGE
® 
Bis-Tris gel was stained with Coomassie Blue after blotting procedure to detect 
the remaining proteins and to determine whether equal amounts of extracts were loaded. 
 
In contrast to liver and heart extracts, faint bands representing 3’P product were observed 
in both WT and Neil1/Neil2 D-KO when intact AP site was processed using brain 
extracts (Figure 4.6). No significant differences (p > 0.1) were observed in the intensity of 
the 3’P product between WT and Neil1/Neil2 D-KO, suggesting that enzymes other than 
Neil1 and Neil2 are responsible for producing the 3’P product. This was further 
investigated using nicked AP sites with a 3’dRP terminus. 
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4.3.2 Processing of nicked AP sites 
To investigate how the β-elimination product was further processed in BER, 5’end-
labeled DNA substrates containing AP sites on the 15th position were nicked with E. coli 
Nth to produce a 3’dRP terminus.  
 
When WT and Neil1/Neil2 D-KO whole-cell extracts prepared from liver, heart or brain 
were added to nicked AP site substrate, the 3’dRP terminus was further processed to both 
3’OH and 3’P products (Figure 4.8). In contrast to the processing of intact AP sites where 
the 3’P product was only observed using brain extracts, the 3’dRP terminus was further 
processed to generate the 3’P product in extracts from all three organs.  However, the 
abundance of 3’P product is substantially higher in brain when compared to liver and 
heart. No significant differences in the yielded 3’P product (p > 0,1) was observed 
between WT and Neil1/Neil2 D-KO, suggesting that enzymes other than Neil1 and Neil2 
are responsible for processing the 3’dRP.   
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Figure 4.8.  3’P product (%) generated from 
32
P-5’end-labeled 40-mer DNA substrate containing nicked 
AP site with a 3’dRP terminus opposite G. AP site opposite other bases showed similar results as well. 
The different amounts of extracts that were incubated with a DNA substrate containing nicked AP site 
(10 fmol) for 30 min at 37 °C, are indicated. Purified APE1 (10 ng) NEIL1 (10 ng) were used as positive 
controls for 3’OH and 3’P termini, respectively. Experiments were repeated several times, one 
representative experiment is shown. Cleaved DNA substrates were separated from intact DNA 
substrates by 20% denaturing PAGE and visualized by phosphorimaging. The results were quantified 
using ImageQuant TL and the background was subtracted during quantification. Means and standard 
deviations were calculated using five or six parallels of each genotype. p values were calculated using 
statistical two-tailed T-test and a 90% confidence interval.  
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A possible candidate for generation of the 3’P product is Tdp1, which is shown to act on 
different 3’blocking lesions (Dexheimer et al., 2008;Nilsen et al., 2012). To further 
investigate whether the generated 3’P products were caused by Tdp1, 5 mM sodium 
orthovandate was used to inhibit the activity of Tdp1. The inhibition resulted in the 
abrogation of the 3’P product, indicating that Tdp1 was indeed responsible for generating 
the 3’P terminus. The extracts of WT and D-KO prepared from liver with and without 5 
mM sodium orthovanadate are shown (Figure 4.9). Similar results were obtained when 
extracts from heart and brain were used, however, only one representative experiment is 
presented. 1 ng S. pombe Tdp1 was also included to observe the inhibition efficiency, 
showing that 5 mM sodium orthovandate is sufficient to achieve full inhibition.  
 
  
Figure 4.9. Inhibition of the activity of Tdp1 upon 
32
P-5’end-labeled 40-mer DNA substrate 
containing nicked AP site with a 3’dRP terminus opposite G. (A) 1 µg whole-cell extracts derived 
from WT and Neil1/Neil2 D-KO liver and 5 mM sodium ortho vanadate were mixed and 
incubated with a DNA substrate containing nicked AP site (10 fmol). “+” and “-“ denotes 
reactions with and without 5 mM  sodium orthovanadate, respectively.  Cleaved DNA substrates 
were separated from intact DNA substrates by 20% denaturing PAGE and visualized by 
phosphorimaging. Purified APE1 (10 ng) NEIL1 (10 ng) were used as positive controls for 3’OH 
and 3’P termini, respectively. S. pombe Tdp1 (1 ng) was also used as a control to investigate the 
efficiency of the inhibitor. Experiments were repeated twice, one representative experiment is 
shown. (B) Schematic representation of (A). The results were quantified using ImageQuant TL 
and the background was subtracted during quantification. The blue and red bars denote the 
fraction of 3’P product in reactions without and with inhibitor, respectively.  
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4.3.3 Processing of intact AP site using 3’end-labeled DNA substrate 
The 3’end-labeled experiments were performed to better evaluate the contribution of 
Nth1 in AP site incision.  
 
Whole-cell extracts from WT and D-KO were incubated with 32P-3’end-labeled DNA 
substrate containing an intact AP site opposite C, and the DNA products were analyzed 
using 20% denaturing sequencing gels. Since the 24-mer DNA substrate was 32P-labeled 
on the 3’end, the product of Nth1 upon cleavage represented the shortest fragment with a 
5’P terminus. This is in contrast with the 5’end-labeled substrates, where the activity of 
Nth1 produced the largest fragment with a 3’dRP terminus. Thus, when using 3’end-
labeled DNA substrates, Ape1, represents the largest fragment with a 5’dRP. The activity 
of Neil enzymes, if any, will appear as a 5’P product, since the β-elimination step is 
performed closest to the 3’end prior to the δ-elimination step. 
 
When 2 mM Mg2+ was included, Ape1 was responsible for the main incision activity, 
representing ~65% of the total cleaving activity in heart and ~100% in liver and brain. 
However in the absence of Mg2+, the 5’dRP and 5’P product was detected in 
approximately 50/50 distribution independent of organ (Figure 4.10). Although Nth1 is 
primarily responsible for generating the 5’P product, one cannot disregard the possibility 
that Pol β may also contribute to some extent in the processing of 5’dRP to 5’P product. 
In addition, only 1/10 amount of extracts were sufficient to detect the products when 
Mg2+ was included, compared to the samples without Mg2+ stimulation. 
 
No statistical tests were performed to determine any significant differences between WT 
and Neil1/Neil2 D-KO, since only two extracts from each genotype was used during 
experiments with 3’end-labeled substrates. However, quantification analysis suggested no 
substantial differences between the WT and Neil1/Neil2 D-KO, which are consistent with 
the results obtained by using 5’end-labeled DNA substrates, suggesting that the 
contribution of Neil enzymes is not substantial compared to Ape1 and Nth1 in mice. 
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Figure 4.10. Processing of intact AP site opposite C using 
32
P-3’end-labeled 24-mer DNA 
substrate in WT and Neil1/Neil2 D-KO whole-cell extracts prepared from liver, heart and brain. 
The different amounts of extracts are indicated and were incubated with a DNA substrate 
containing intact AP site (10 fmol) for 30 min at 37 °C. 2 mM Mg
2+
 was included when indicated. 
Cleaved DNA substrates were separated from intact DNA substrates by 20% denaturing PAGE 
and visualized by phosphorimaging. Purified APE1 (10 ng) and E. coli Nth (2 U/µl) were used as 
positive controls for 5’dRP and 5’P termini, respectively. Experiments were repeated twice, one 
representative experiment is shown.  
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4.4 Down-regulation of NTH1 and TDP1 
To determine the effect on processing of AP sites when the expression of NTH1 or TDP1 
were down-regulated in humans, different cell lines like HeLa S3 and HaCaT were used. 
In order to achieve knockdown of NTH1 and TDP1, transfection with siRNA specific to 
the respective genes was performed. 
4.4.1 Optimization of transfection conditions 
Transfection conditions, like the amount of siRNA, Lipofectamine™ RNAiMAX and cell 
type, were optimized to achieve highest possible transfection efficiencies and maximum 
knockdown. 
Optimal transfection conditions were first determined in HeLa S3 cells, by using 1.2-30 
pmol siRNA in combination with 0.5, 1.0 and 1.5 µl Lipofectamine™ RNAiMAX. 
Transfected cells were harvested in protein-cracking buffer and used in Western blot 
analysis to evaluate reduction in protein quantities. Only the combination of 1.5 µl 
Lipofectamine™ RNAiMAX and 1.2 pmol of NTHL1-siRNA exhibited substantial down-
regulation of NTH1 (Figure 4.11A). In contrast, TDP1 was down-regulated under several 
combinations, including the combination where 1.5 µl Lipofectamine™ RNAiMAX and 
1.2 pmol TDP1-siRNA was used (Figure 4.11B). Relative quantity analysis in ImageLab 
BioRad indicated ~50% down-regulation of NTH1 in cells transfected with NTHL1-
siRNA, and ~65% down-regulation of TDP1 in cells transfected with TDP1-siRNA. 
Control cells transfected with non-targeting siRNA were used as reference. Different 
amount of siRNA used in combination with 1.5 µl Lipofectamine™ RNAiMAX are 
shown (Figure 4.11). Experiments where either 0.5 or 1.0 µl Lipofectamine™ 
RNAiMAX was used in combinations with various amount of siRNA, indicated similar 
results. The presence of endogenous NTH1 and TDP1 was demonstrated in the control 
samples. Although several bands of different sizes were detected, one band represented 
the expected size of target protein, as indicated.  Parallels were made for each 
combination, and included as quality control.  
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Figure 4.11. Determination of optimal transfection conditions using HeLa S3 cells line. Different 
amount of siRNA was used in combination with 1.5 µl Lipofectamine™ RNAiMAX, to determine 
which combination resulted in down-regulation. Combination where 0.5 and 1.0 µl 
Lipofectamine™ RNAiMAX was used indicated similar results. 4x10
4
cells were seeded and 
transfected cells were harvested in protein-cracking buffer and used in Western blot analysis.  
(A)  NTH1 and (B) TDP1 was detected using 1:500 and 1:2,000 dilution of Anti-NTH1 antibody 
and Anti-TDP1 antibody, respectively. The red arrow indicates the bands of interest. (A) NTH1 
(20 ng) and (B) HaCaT cell lysate (30 µg) was included as positive controls. “-“ denotes HeLa S3 
cells used as control for endogenous (A) NTH1 and (B) TDP1. Dublicates were made for each 
transfection condition.  MagicMark™ XP was used as Western protein standard.  
 
 
4.4.2 Transfection of HeLa S3 cells to down-regulate NTH1 or TDP1 
To investigate the processing of AP sites when NTH1 or TDP1 was down-regulated, 
whole-cell protein extracts were prepared from newly transfected cells. Based upon the 
testing of the transfection conditions, 1.5 µl Lipofectamine™ RNAiMAX and 1.2 pmol 
siRNA resulted in successful down-regulation of NTH1 and TDP1 in 4x104 cells. Thus, 
this ratio was further used to achieve down-regulation, using five times more cells.  
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Western blot was performed on 25 µg of NTH1 knockdown (KD) extracts, TDP1 KD 
extracts and control extracts. Relative quantity analysis in ImageLab BioRad indicated 
approximately 65 % down-regulation of TDP1 in TDP1 KD extracts (Figure 4.12A). 
However, down-regulation of NTH1 was not successful (Figure 4.12B), which was 
somewhat unexpected since down-regulation of NTH1 was achieved during optimization. 
 
Figure 4.12. Western blot performed on 25 µg (A) TDP1 and (B) NTH1 KD extracts prepared 
from transfected HeLa S3 cells. 7.5 µl Lipofectamine™ RNAiMAX and 6 pmol siRNA was used 
to transfect 2x10
5
 cells. Biological duplicates were prepared when targeted gene were down-
regulated. (A) TDP1 and (B) NTH1 was detected using 1:500 and 1:2,000 dilution of Anti-NTH1 
antibody and Anti-TDP1 antibody, respectively. The red arrow indicates the bands of interest. 
(A) HaCaT cell lysate (20 µg) and (B) NTH1 (20 ng) was included as positive controls. 
MagicMark™ XP was used as Western protein standard.  
 
Even though bands of expected size for NTH1 and TDP1 were detected in Western, they 
may represent false positive bands, due to unspecific binding of the antibody to proteins 
with similar masses as the target proteins. Thus, biochemical approaches was also used to 
verify the results obtained from Western blot analysis. 
4.4.3 Evaluating down-regulation of NTH1 by biochemical analysis 
Although the NTH1 KD extracts showed no down-regulation of NTH1, a sodium 
borohydride-mediated trapping assay was performed to verify the results. The β-
elimination activity of NTH1 occurs via a Schiff base intermediate. In the presence of the 
reducing agent, sodium borohydride, the enzyme-DNA complex is irreversibly linked and 
thus migrate slower than the free DNA substrates (Fromme and Verdine, 2003). Trapped 
products of the same size as purified NTH1, used as positive control, were observed in 
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both control and NTH1 KD extracts, indicating the presence of NTH1-DNA complex 
(Figure 4.13). In addition, the intensity of the bands is not reduced in NTH1 KD extracts 
compared to control extracts, indicating no substantial down-regulation of NTH1. This is 
consistent with the results obtained from Western blot analysis.  
 
 
Figure 4.13. Formation of trapped complexes of protein and 5’end-labeled DNA substrate 
containing 5-OHU opposite G. DNA substrate (10 fmol) and different amounts of extract 
indicated were incubated at 37 °C for 30 min in the presence of 100 mM sodium borohydride. 
NEIL1 (50 ng), NEIL2 (50 ng), E. coli Nth (2 U/µl) and NTH1 (50 ng) was included as positive 
controls. Protein-DNA substrate complexes were separated from DNA substrate by SDS-PAGE 
using 10% NuPAGE
® 
Bis-Tris gel. The position of the trapped complex is indicated. Experiments 
were repeated with biological dublicate extracts, one representative experiment is shown.  
 
4.4.4 Evaluating down-regulation of TDP1 by biochemical analysis 
TDP1 KD extracts indicated down-regulation of TDP1 by ~65%, using Western blot. To 
verify this down-regulation, the TDP1 KD extracts were tested against a 5’end-labeled 
DNA substrate containing phophotyrosine at the 3‘end, which is known to be efficiently 
processed by TDP1 (Yang et al., 1996). 
 
When using control extracts, phosphotyrosine was efficiently processed to 3’P terminus, 
as expected. However, the removal of phosphotyrosine was reduced by ~55% when using 
the TDP1 KD extracts, indicating that TDP1 levels in KD extracts are reduced compared 
to the control extracts (Figure 4.14), as also seen in Western blot analysis. Thus, the 
TDP1 KD extracts and control extracts were further used to investigate the processing of 
AP site, addressed in section 4.5. 
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Figure 4.14. Processing of 
32
P-5’end-labeled 20-mer DNA substrate containing phosphotyrosine 
(pTyr ) on the 3’end. The different amounts of extracts incubated with DNA substrate (10 fmol), 
for 30 min at 37 °C, are indicated in each figure. Cleaved DNA substrates were separated from 
intact DNA substrates by 20% denaturing PAGE and visualized by phosphorimaging. The 
results were quantified using ImageQuant TL and the background was subtracted during 
quantification. S. pombe Tdp1 (1 ng) was used as positive control for 3’P terminus. Experiments 
were repeated with biological dublicate extracts, one representative experiment is shown.  
 
4.4.5 Further attempts to down-regulate NTH1 
After several unsuccessful attempts to down-regulate NTH1 in HeLa S3 cells, different 
combinations of Lipofectamine™ RNAiMAX and NTHL1-siRNA were also tested in 
HaCaT cells. However, no down-regulation of NTH1 was observed in the HaCaT cells 
either (data not shown). Meanwhile, mycoplasma contamination was detected in both 
HeLa S3 and HaCaT cell lines during a routine control, which could explain the 
unsuccessful down-regulation of NTH1 (Appendix F). 
Thus, a healthy HeLa S3 cell line was used to down-regulate NTH1 again. The absence of 
mycoplasma was confirmed (data not shown). In addition, this time the success of down-
regulation was evaluated not only by Western Blot but also by RT-PCR.  
4.4.6 Evaluation of down-regulation using RT-PCR 
Total RNA was first isolated from the transfected cells and converted to cDNA by reverse 
transcription. The gene for β-Actin, ACTB, was chosen as the endogenous reference for 
normalization.  
To determine the amplification efficiencies of the target genes; NTHL1 and ACTB, series 
of 1:5 dilutions were prepared from the control cDNA sample using gene-specific 
primers. Positive controls and negative controls were also included. Each sample was 
amplified in a two-step RT-PCR and standard curves were constructed by plotting 
different CT values of standard dilutions against the logarithm of the amount of cDNA 
template (Appendix G). Amplifications efficiencies for NTHL1 and the reference gene 
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were determined to 85% and 99%, as expected. The amplification efficiencies between 
reference and target genes are usually different due to unequal primer annealing.  
Based on the information gained from the standard curves, 1:10 dilution of the cDNA 
samples prepared from control cells and cells transfected with siRNA specific for NTHL1, 
were used to evaluate down-regulation of NTHL1. Gene knockdown efficiency was 
calculated by an automated relative quantification method in the StepOne™ v2.1 
Software, where the ratio between the amount of target gene and the reference gene in a 
control sample was determined. This ratio was then used to compare cDNA from KD 
cells extracts and control cells. Melting curves for each target gene were analyzed for 
quality control and the clear peak demonstrate the absence of primer-dimers and the 
presence of one specific PCR product (Appendix G). 
The analysis showed no down-regulation of NTHL1 gene in transfected cells compared to 
control cells (Figure 4.15A), which was also confirmed using Western blot analysis on 25 
µg NTH1 KD extracts and control extracts (Figure 4.15B).  
 
 
Figure 4.15. Evaluation of the gene down-regulation of NTH1. (A) RT-PCR: relative mRNA 
levels of NTHL1 were calculated by comparative method of relative quantification using 
StepOne™ V2.1 Software. The relative expression of mRNA levels of NTHL1 gene is shown in 
control cells and NTHL1-siRNA transfected cells. (I) and (II) represent biological duplicates, 
included as quality control. The mRNA expression levels of NTHL1 in control cDNA (I) is set as 
reference. Triplicates were made from each extract and normalized to β- Actin, used as the 
endogenous reference. Error bars indicate standard deviations of the means of three technical 
replicates. (B) Western blot performed on 25 µg biological duplicates of control extracts NTH1 
KD extracts prepared from NTHL1-siRNA transfected HeLa S3 cells.  Endogenous NTH1 was 
detected using 1:500 Anti-NTH1 antibody. The red arrow indicates the bands of interest. NTH1 
(10 ng) was included as positive controls for endogenous NTH1. MagicMark™ XP was used as 
Western protein standard.  
  
  4 Results  
 
64 
 
4.5 Biochemical assays performed on TDP1 KD extracts 
Control and TDP1 KD extracts, from section 4.4.4 were used to investigate the processing 
of 5’end-labeled DNA substrates containing intact or nicked AP sites. Due to the 
dominating activity of APE1 in the processing of AP sites, an APE1-inhibitor was used to 
reduce its activity, which could provide better insight in the roles of TDP1 and NTH1. 
4.5.1 Processing of intact AP sites using APE1 inhibitor 
When 1 µg control extract was used, ~65% of the intact AP sites were processed to 3’OH, 
whereas ~20% of the total cleavage product was observed as 3’dRP product. The 
remaining ~15% were processed to 3’P product.   
 
The band of 3’OH products represent the total amount of 3’OH generated mainly by the 
activity of APE1 that either incise the AP site to generate 3’OH directly or further 
processes the 3’dRP terminus produced by the actions of NTH1. However, one must also 
take into consideration that PNKP is also capable of processing the 3’P product to 3’OH, 
even though its contribution is not significant compared to APE1. 
 
To determine the fraction of the 3’OH products that are generated from 3’dRP, the 
activity of APE1 was inhibited using 500 µM myricetin, an APE1 inhibitor. 1 µg control 
extract was sufficient to reduce the intensities of the 3’OH bands from representing ~65% 
of the total activity to ~35% of the total activity (Figure 4.16A). This is consistent with 
the fact that the intensity of the 3’dRP band increased by ~30% when myricetin was 
added, suggesting that ~30% of the 3’dRP generated by NTH1 is further processed to 
3’OH by APE1. 
 
In addition, when myricetin was added to control extracts, a reduction in the intensity of 
the 3’P product was also observed, suggesting that the action of TDP1 is also inhibited by 
myricetin. Indeed, this was confirmed when the activity of 1 ng of S. pombe Tdp1 was 
inhibited by 500 µM myricetin. In fact, myricetin is capable of inhibiting TDP1 in 
approximately the same extent as sodium orthovanadate (Figure 4.16B). 
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Figure 4.16. Processing of AP site opposite G using 
32
P-5’end-labeled 40-mer DNA substrate.  
Cleaved DNA substrates were separated from intact DNA substrates by 20% denaturing PAGE 
and visualized by phosphorimaging. The results were quantified using ImageQuant TL and the 
background was subtracted during quantification. (A) Different amounts of extracts were 
incubated with a DNA substrate containing intact AP site (10 fmol), for 30 min at 37 °C, and are 
indicated. “-“ and “+myricetin” denotes reactions with and without 500 µM APE1 inhibitor, 
respectively. Purified E. coli Nth (2 U/µl), NEIL1 (10 ng), APE1 (10 ng) were used as markers for 
3’dRP, 3’P and 3’OH termini, respectively. Experiments were repeated twice, one representative 
experiment is shown. (B)  The activity of S. pombe Tdp1 (1 ng) and APE1 (10 ng) was inhibited 
using either 5 mM sodium orthovanadate or 500 µM myricetin. S. pombe Tdp1 (1 ng) and APE1 
(10 ng) was incubated, for 30 min at 37 °C, with DNA substrate containing nicked AP site or 
intact AP site. Experiments were repeated twice, one representative experiment is shown. 
 
The 3’P products were detected in reduced quantity in TDP1 KD extracts compared to 
control extracts, which was expected. In addition, when TDP1 KD extracts were used, the 
3’dRP product was observed to represent only ~10% of the total cleavage product, 
whereas the 3’OH product represent the remaining ~90%. This increase in the 3’OH 
product might suggest an up-regulation of APE1 in TDP1 KD extracts.  
 
When 500 µM myricetin was added the intensity of the 3’dRP band increased by ~35%, 
due to the accumulation of the 3’dRP product when APE1 is inhibited, which is 
consistent with the increase observed in control extracts.    
4.5.2 Processing of nicked AP site using APE1 inhibitor 
To demonstrate that the 3’dRP is in fact further processed by either APE1 or TDP1, a 
5’end-labeled DNA substrate containing a nicked AP site was used.  Both 3’OH and 3’P 
product were generated in control extracts (Figure 4.17). To ensure that the 3’P product 
was indeed produced by the actions of TDP1, the activity of TDP1 was inhibited by 5 
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mM sodium orthovanadate in control extracts, resulting in reduction of the 3’P products 
by ~80%. Thus, the reduction of the 3’P product was seen in both TDP1 KD extracts and 
by the use of sodium orthovanadate, suggesting that the 3’P product indeed result from 
TDP1 activity, and that NEIL1 and NEIL2 in HeLa S3 cells have a non-essential role in 
AP site processing.  
 
In addition, when TDP1 KD extracts were used, reduced 3’P and increased 3’OH 
products were observed when compared to control extracts, supporting the idea that 
APE1 might be up-regulated when TDP1 is down-regulated. 
 
Figure 4.17. Processing of AP site nicked with E. coli Nth opposite G using TDP1 KD extract. The 
different amounts of extracts incubated with nicked DNA substrate (10 fmol) for 30 min at 37 °C, 
are indicated. Cleaved DNA substrates were separated from intact DNA substrates by 20% 
denaturing PAGE and visualized by phosphorimaging. The results were quantified using 
ImageQuant TL and the background was subtracted during quantification. Purified S. pombe 
Tdp1 (1 ng) and APE1 (10 ng) were used as markers for 3’P and 3’OH, respectively. 
Experiments were repeated twice, one representative experiment is shown. 
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5 Discussion 
AP sites are one of the most frequent lesions in cellular DNA and their repair is essential 
for genomic stability. In this study, the processing of AP sites were investigated by using 
recombinant NTH1, KO mice models and knockdown of immortalized human cell lines.  
5.1 Cleaving activity of recombinant NTH1 
Initially, the cleaving activity of recombinant NTH1 was demonstrated upon ss and ds 
DNA substrate containing either an AP site or 5-OHC. These assays revealed that NTH1 
was active upon ds and ss DNA substrate containing AP site, however, the processing of 
ss DNA substrate was observed to be 4-fold less than processing of ds DNA substrate. 
With 20 ng NTH1, the ss DNA substrate was cleaved only ~15% compared to ~60% for 
the corresponding ds DNA substrate. Also when 5-OHC was processed by NTH1, only 
~20% of the ss DNA substrate was cleaved. These results show that NTH1 primarily is 
active only upon ds DNA, and can to some extent also process an AP site or 5-OHC in ss 
DNA substrates.  Thus, the activity of NTH1 upon ss DNA substrates is probably of less 
biological importance in vivo. This is in agreement with the fact that NTH1 is known to 
be only active with ds DNA, as described in the introduction (Hegde et al., 2012).  
 
Although NTH1 possess both DNA glycosylase and AP lyase activities, these two 
activities can occur at different rates. For instance, the DNA glycosylase activity of 
NTH1 has been shown to be 7-fold greater than its AP lyase activity when the DNA 
substrate contains a Tg opposite A (Tg:A) (Marenstein et al., 2003). Thus, the efficiency 
of DNA glycosylase and AP lyase activities seem to depend on not only the damaged 
base but also on the complementary base.  
 
The DNA glycosylase and AP lyase activities of NTH1 were found to be mostly coupled 
when 5-OHC was processed. However, the ~10% increase in cleaving activity when 
NaOH was added,  represent the fraction of NTH1’s activity that only removed the base 
to generate an AP site, which in turn was hydrolyzed by NaOH. The appearance of two 
bands when NaOH was added to the reactions can be explained by NaOH’s ability to 
cleave on both the 5’ and 3’ sides of the AP site.  
 
Furthermore, the processing of ds DNA substrates containing AP site was not affected 
when different bases were used opposite the AP site. This was somewhat unexpected 
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since the activity of NTH1 has been demonstrated to be affected by the nature of the 
opposite base. For instance, NTH1 acts only as a monofunctional DNA glycosylase upon 
Tg:G, but demonstrate both DNA glycosylase and AP lyase activity upon Tg:A 
(Marenstein et al., 2003). The dependency on the complementary base for DNA 
glycosylase and AP lyase activities is supported by the fact that NTH1 probably interacts 
with both DNA strands upon binding and processing, as revealed by the three-
dimensional structure of E. coli Nth (Fromme and Verdine, 2003). An important aspect to 
consider is that the opposite base may have a greater role when it forms hydrogen bonds 
with the damaged base. In the case of AP sites, however, the opposite base may not have 
a great importance, due to lack of base pairing. 
 
In addition, it was tempting to speculate whether NTH1 was also capable of acting 
downstream of APE1 in BER to process the 5’dRP terminus either parallel with POL β or 
as a back-up for POL β. This was investigated by using a 3’end-labeled DNA substrate 
containing an APE1-nicked AP site to generate a 5’dRP terminus.  Our results 
demonstrated that 5’dRP was a poor substrate for NTH1, requiring 10-fold more enzyme 
than for the intact AP site. Thus, NTH1 manages to process the 5’dRP terminus when the 
system is pushed and the protein is added in excess, but the contribution of NTH1 in 
processing of 5’dRP have probably little, if any, biological importance in vivo.  
 
5.2 Repair of AP sites in mice 
Neil1/Neil2 D-KO and WT mice have been used to investigate the repair of AP sites 
using whole-cell extracts from heart, liver and brain.  
 
Contribution of Neil enzymes  
No statistical significant differences in cleaving activity were ever observed between WT 
and Neil1/Neil2 D-KO, suggesting a non-essential role of Neil1 and Neil2 in AP site 
incision. Even though the Neil enzymes cleave AP sites, their actions might be of minor 
importance in the presence of Ape1.  However, it is important to consider the possibility 
that Neil enzymes may contribute more significantly in the repair of base damages than 
AP sites. Indeed, this can be supported by the fact that recombinant NEIL1 and NEIL2 
have the ability to initiate repair of 5-OHU in the absence APE1 by removing the 
damaged base and then processing the generated AP site (Das et al., 2006). Thus, one 
may speculate whether Neil enzymes need their DNA glycosylase activity, in order to 
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further proceed with their AP lyase acitivity. If the damaged base is already removed, 
other enzymes are more likely to initiate the repair of the AP site, making the contribution 
of Neil enzymes not substantial enough to be detected. It is also a possibility that Neil 
enzymes may function as a back-up repair pathway for AP sites and contribute more in 
the absence of Ape1.  
 
Nth1’s activity in Neil1/Neil2 D -KO and WT  
Processing of intact AP sites using WT and D-KO extracts showed that AP sites are 
mainly processed by the activity of Ape1. The 3’dRP product generated by Nth1 was also 
detected, although to a lesser extent than 3’OH. No change in the activity of Nth1 was 
observed when the cleavage products were compared between WT and Neil1/Neil2 D-
KO, suggesting that the level of Nth1 was not changed by the absence of Neil enzymes. It 
was tempting to speculate whether the levels of Nth1 were up-regulated in Neil1/Neil2 D-
KO mice, due to the fact that Nth1 represent the only remaining bifuntional DNA 
glycosylase in mammals acting on oxidized pyrimidines when Neil enzymes are absent 
(Takao et al., 2002). However, no up-regulation of Nth1 was demonstrated on a 
quantitative level by Western blot analysis when Neil1/Neil2 D-KO was compared to 
WT. Nevertheless, the lack of up-regulation should also be confirmed by monitoring 
levels of gene expression. 
 
In addition, β-Actin included as loading control showed equal amounts of β-Actin within 
each organ as expected, indicating that equal amounts of extracts were loaded. However, 
the levels of β-Actin were observed to differ between the organs (Figure 4.7A). To our 
knowledge β-Actin is expressed in all the organs, but with significant difference in their 
expression levels (Kouadjo et al., 2007). The fact that β-Actin was not even detected in 
heart extracts, was unexpected. However, the Coomassie Blue-stained gel demonstrated 
that equal amount of heart extracts were loaded onto the gel, and thus made it possible to 
compare the Nth1 levels in heart extracts of WT and D-KO too.  
 
Contribution of NTH1 in AP site repair  
To determine the contribution of Nth1 to AP site repair in mice, the bands representing 
3’dRP was quantified, which proved to be a challenge since the 3’dRP product appeared 
as diffused smears instead of clear bands. The software used to quantify the processed 
products overestimated the yield of the 3’dRP product, resulting in inaccurate 
  5 Discussion 
 
70 
 
quantifications. Thus, there is an uncertainty in the estimated fractions that represent the 
abundance of 3’dRP compared to 3’OH products (Figure 4.6). 
 
Regardless, based on the visual examination of the bands, it is clear that the 3’OH product 
is more abundant. However, a fraction on the total 3’OH product may also represent the 
activity of Nth1 indirectly. Indeed, the processing of DNA substrates containing nicked 
AP sites demonstrated that the 3’dRP terminus can be further processed to 3’OH or 3’P 
by the actions of Ape1 or Tdp1, respectively. One must also take into consideration that 
the product of Tdp1, 3’P, is also further processed to 3’OH by the actions of Pnkp. Thus, 
total 3’OH product generated when intact or nicked AP site are processed, is not only 
represented by the activity of Ape1, but also by Pnkp. However, it is important to 
emphasize that the contribution of Pnkp is not substantial compared to Ape1, due to the 
fact that Ape1 is responsible for ~95% of the AP site processing (Chen et al., 1991).  
 
Since Ape1 not only incise the AP site directly, but also further processes the 3’dRP, it is 
impossible to determine the total contribution of Nth1. Evaluation of the contribution of 
Nth1, as well as Tdp1, can therefore be complicated, due to the fact that there are several 
enzymes involved in the processing either directly or through protein-protein interactions.  
 
To avoid the Ape1 processing of the 3’dRP products, DNA substrates were also 32P-
labeled on the 3’end to investigate the abundance of the 5’P generated by Nth1. One may 
speculate whether a fraction of the 5’P product can also result from the action of Pol β 
who is capable of processing the 5’dRP to 5’P. However, as shown by Allison et al., 
2001, Pol β acts in a coordinated manner subsequently to the activity of APE1, by adding 
a single nucleotide to the 3’end of the incised AP site, as it simultaneously removes the 
5’dRP residue. In addition, Pol β has shown to process the 5’dRP terminus in a Mg2+-
dependent manner (Matsumoto and Kim, 1995). Thus, it seems like if Pol β requires 
incorporation of a single nucleotide, to process the 5’dRP product to 5’P. Since neither 
Mg2+ nor nucleotides were added to the reactions where 5’P product was observed, one 
can assume that the contribution of Pol β is of minor, if any, importance to the generated 
5’P terminus in these assays. 
 
Thus, based on the results obtained using 5’end-labeled and 3’end-labeled DNA 
substrates, it is only possible to establish that Nth1 is indeed involved in the AP site 
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processing in mice, but the total contribution of Nth1 cannot be determined. A better 
picture of the situation can be obtained by inhibiting the activity of either Pol β or Ape1. 
However, full inhibition of their activities, especially the activity of Ape1 is not possible 
to accomplish, without affecting other DNA repair processes, which in turn will provide 
inaccurate results. Indeed, the essential role of both Ape1 and Pol β in BER can be 
emphasized by the fact that Pol β-deficient mice have been shown to die immediately 
after birth, whereas Ape1-deficient mice die in the early embryonic stage (Sugo et al., 
2000;Zou et al., 2007).  
 
Contribution of Tdp1  
As mentioned previously the 3’dRP product generated by Nth1 was shown to be further 
processed to 3’P by the activity of Tdp1. This was somewhat unexpected since the 
generated 3’P product was expected to result from the activities of Neil enzymes. 
Furthermore, Lebedeva et al., 2011 had shown that recombinant human TDP1 is capable 
of processing the 3’dRP termini, however, the in vivo significance of this observation was 
not addressed.  
 
When nicked AP site with a 3’dRP was processed by Ape1 and Tdp1, near equal amounts 
of the 3’OH and 3’P products were produced in all three organs, which is in contrast to 
when intact AP sites were processed. Interestingly, at least twice as much 3’P product 
was generated in brain as in liver and heart. Also when intact AP sites were being 
processed in different mice organs, the Tdp1’s activity was only seen in brain. These 
findings suggest that Tdp1 may be present in larger quantities in brain or it may have 
some modifications that enhance its activity in brain.  The importance of Tdp1 in brain 
function is also seen in the neurodegenerative disease, SCAN1, that is caused by a 
homozygous mutation in the TDP1 gene (Takashima et al., 2002). It is believed that the 
absence of TDP1 in mammals can cause accumulation of the TOP1 SSB and 
hypersensitivity towards CPT, as well as increase the vulnerability of neurons due to high 
levels of oxidative stress and low level of antioxidant enzymes. Furthermore, TDP1 
deficiency in mammalian cells have also shown reduced repair capacity for oxidative 
SSB, suggesting that the actions of TDP1 are not only restricted to Top1-DNA complexes 
(El-Khamisy et al., 2005;Interthal et al., 2005).  
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Differences observed between organs  
One additional noteworthy observation was that processing of intact AP site using liver 
extracts required less amount of protein extract compared to heart and brain that required 
approximately twice as much protein extract to exhibit corresponding processing of AP 
sites. It is conceivable that the more efficient processing of intact AP sites in liver may be 
explained by the fact that liver is responsible for the main detoxification processes and 
thus requires more efficient repair of DNA damages. It can also be speculated in whether 
the proteins of interest are present in larger quantities in the protein extracts prepared 
from liver compared to the other organs, which in fact has not yet been determined. This 
can be determined by investigating expression levels of the target proteins in the different 
organs. Other reasons for observing more efficient AP site processing in liver can be that 
liver proteins may have different types of modifications compared to the other organs, as 
well as other protein partners that facilitate the processing by protein-protein interactions.    
 
5.3 Down-regulation of NTH1 or TDP1 in HeLa S3 cells 
To down-regulate the expression of NTH1 or TDP1, different cell lines were transfected 
with siRNA specific for NTHL1 or TDP1 gene.  
 
Evaluation of transfected cells  
Optimal transfection conditions were determined to 1.2 pmol siRNA and 1.5 µl 
Lipofectamine™ RNAiMAX, and cells were transfected at 50-70% confluency. It is 
important that cells are proliferating exponentially when transfected. In addition, cells 
should be harvested before they reach confluence, due to contact inhibition that prevents 
the cells from dividing when they come in contact with each other. Immortal cell lines, 
however, continue proliferating even after they reach confluence, but result in 
deterioration after two doublings. Thus, optimizing seeding densities and transfecting 
cells at suitable confluency is essential for achieving successful down-regulation.  
 
When testing optimal transfection conditions in HeLa cells, several combinations of 
siRNA and transfection reagent resulted in down-regulation of TDP1. In contrast, only 
one combination resulted in down-regulation of NTH1, suggesting that the down-
regulation of TDP1 was more robust than that of NTH1.  
 
Even though successful down-regulation of both NTH1 and TDP1 was observed in at 
least one of the transfection conditions tested, down-regulation of NTH1 was not 
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achieved in later experiments. This was somewhat unexpected since the purchased 
siRNA, containing pools of three target-specific siRNAs, has been designed and tested 
solely to down-regulate gene expression of NTHL1 (Santa Cruz®, 2012). TDP1 on the 
other hand, was estimated to be ~65% down-regulated by Western blot analysis. This 
down-regulation was, however, not confirmed on mRNA level using RT-PCR. Thus, 
biochemical approaches were used to evaluate down-regulation. Since the activity on a 
phosphotyrosine-containing DNA substrate was reduced by ~55% in the corresponding 
extracts, one can consider the down-regulation to be biological relevant. Biochemical 
approaches used to evaluate down-regulation are further discussed in the end of this 
section.  
 
Furthermore, a routine contamination check detected the presence of mycoplasma in the 
HeLa cell line used to down-regulate NTH1. Mycoplasma contamination can influence 
the experimental results by causing alterations in growth characteristic, enzyme patterns, 
cell membrane composition and chromosomal abnormalities. This again can influence the 
experimental results obtained with cell lines and lead to misleading conclusions. Thus, the 
contaminated cells, may have affected the transfection and knockdown efficiencies, 
resulting in unsuccessful down-regulation of NTH1 (van Kuppeveld et al., 1994).   
 
Nevertheless, even when a fresh and uncontaminated HeLa S3 cell line was used, no 
down-regulation of NTH1 was observed. It is uncertain whether the unsuccessful down-
regulation is caused by low transfection efficiencies due to low siRNA uptake in cells or 
by low knockdown efficiencies. The transfection efficiency, defined by the fraction of 
cells that manages to take up exogenous RNA or DNA successfully, can be determined 
by transfecting cells with a plasmid expressing green fluorescent protein (GFP). The 
expression of GFP can then be examined by using fluorescence microscopy. Another way 
to determine the fraction of siRNA uptake in cells is by fluorescently labeling siRNA and 
use flow cytometry to measure the fraction of cells containing fluorescent siRNA. These 
methods should be included in further studies. 
 
The efficiency of knockdown is always less than the transfection efficiency, due to the 
fact that not all siRNA taken up by the cell will actively contribute to down-regulation of 
the target gene. Once the cells have taken in the siRNA-liposome complex, the fraction of 
siRNA released into the cells that is actually active, varies, since a portion of siRNA 
  5 Discussion 
 
74 
 
released might either be inactivated, degraded or compartmentalized (Bartz et al., 
2011;Rossi, 2005) 
 
It is also important to consider that transient transfections only provides down-regulation 
of the target gene for a limited time, since the transfected genetic material is not 
integrated into the genome. The effect of down-regulation is thus only transient, since the 
siRNA taken in by the cell will get diluted through mitosis or degraded. If the 
transfections efficiencies and knockdown efficiencies are not optimal, the time interval 
the target gene is down-regulated in, is also shortened. Thus, the time frame of the 
experiment is an important parameter to consider, since the effect of transfection only last 
for a limited time period. 
 
Although several studies indicate successful down-regulation of both TDP1 and NTH1 
using transient transfection, stable transfection is the best option especially during a long 
term experiment. However, due to limited time frame, transient transfection was chosen 
to down-regulate the proteins of interest. 
 
Furthermore, in addition to cell health, a lot of other factors that can influence the 
transfection efficiency were also taken into consideration. Number of passages was kept 
at less than 10. The cells were transfected at the confluency recommended by the 
manufacturer and harvested 48 h after transfection as recommended. To ensure that the 
effect of down-regulation was not lost due to long incubation period after transfection, 
transfected cells were also once harvested after 24 h instead of 48 h, without observing 
any successful down-regulation.  
 
To observe down-regulation on mRNA levels, uncontaminated HeLa S3 cells transfected 
with siRNA specific for NTHL1 were also evaluated by RT-PCR, a method that is 
capable of determining if and to what extent mRNA levels of the target gene has been 
down-regulated. Western blot is only capable of evaluating down-regulation on protein 
level and is often supplemented with other methods like RT-PCR or biochemical assays, 
since Western blot may show false positive bands, due to unspecific binding of the 
antibody to proteins with similar masses as the target protein. However, no down-
regulation of NTHL1 was observed on mRNA levels either, which was consistent with the 
results obtained from Western blot analysis or biochemical analysis. 
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Use of RT-PCR to evaluate down-regulation of NTH1 
The two biological replicates representing control cells are demonstrating somewhat 
different mRNA levels of the NTHL1 gene, indicating individual variation in the 
biological system (Figure 4.15).  
 
Since no primer-dimers were observed during the melting curve analysis, one can exclude 
their contribution to any inaccurate results. In addition, the calculated amplifications 
efficiencies were as expected and were used as an indication of how well the gene-
specific primers are able to anneal to their respective genes. Although, the amplification 
efficiency of 100% indicates that the PCR product is doubled during each cycle which is 
optimal during an experiment, most amplification efficiencies are usually calculated to be 
below this due to experimental limitations, such as depletion of PCR components and 
renaturing of PCR products. In addition the difference between amplification efficiencies 
of the target and reference gene were as expected and are caused by various efficiency of 
primer annealing, GC-content of the sequence that are amplified and the size of PCR 
product. Since no fluorescence signal was detected in the negative control included in the 
experiment, any nucleic acid contamination in the samples that could have caused 
inaccurate results was also ruled out.  
 
Use of biochemical approach to evaluate down-regulation  
A biochemical approach was used to demonstrate that NTH1 was not down-regulated in 
NTH1 KD extracts. The trapped protein-DNA complex in both control and NTH1 KD 
extracts appeared to be at the same size as NTH1-DNA complex formed when 
recombinant NTH1 was used as positive control (Figure 4.13). However, the bands 
detected in the extracts seemed to have migrated slightly longer than the recombinant 
NTH1-DNA complex. One explanation may be that endogenous NTH1 in the extracts 
may have PTMs, which the recombinant NTH1 lacks.  
 
Another observation made during the trapping assay was the absence of NEIL1-DNA and 
NEIL2-DNA complexes in control or NTH1 KD extracts, indicating that the levels of 
NEIL1 or NEIL2 were too low to be detected when 8 or 16 µg extracts were used. NTH1, 
on the other hand, was detectable, indicating that NTH1 might be present in larger 
quantities than the NEIL enzymes, which in turn could also help explain why we could 
not observe any susbstantial contribution in AP site processing from Neil enzymes in 
mice.  
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Down-regulation of TDP1 was also evaluated by observing the processing of a 
phosphotyrosine-containing DNA substrate. Less phosphotyrosine was processed in 
TDP1 KD extracts compared to control extracts, indicating successful down-regulation of 
TDP1. The high background signal detected by phosphorimaging, did not interfere with 
the obtained results, but indicates some level of impurity in the DNA substrate (Figure 
4.14).  
 
5.4 Processing of AP sites using HeLa S3 cell line  
The processing of intact AP sites were also investigated using control and TDP1 KD 
extracts prepared from transfected HeLa S3 cells.  
 
Intact AP sites were mainly processed to 3’OH termini, which is consistent with the 
observations made in mice. The fact that 3’dRP and 3’P was observed in less degree than 
3’OH, confirms that APE1 is responsible for most of the AP site processing. 
 
Just like in mice, the 3’P product was generated by the activity of TDP1 acting 
downstream of NTH1 on the 3’dRP termini. Indeed, the abrogation of the 3’P product in 
TDP KD extracts and when TDP1-inhibitor was added to control cells, suggest that 
NEIL1 or NEIL2 are not responsible for generating the 3’P product.  
 
Since the 3’dRP can be further processed to 3’OH and 3’P, it was not possible to 
determine the total contribution of NTH1. In addition, the strong activity of APE1, 
overshadows the contribution of other enzymes involved in the processing of AP site. 
This issue was also raised when AP sites were processed in mice. Thus, in contrast to 
experiments where mice extracts were used, the activity of APE1 was inhibited to some 
extent in control and TDP1 KD extracts by using 500 µM myricetin. A ~30% increase 
was observed in the intensity of the 3’dRP band when the activity of APE1 was inhibited, 
suggesting that ~30% of the 3’dRP is further processed to 3’OH by APE1. This is 
consistent with other studies indicating that APE1 have a greater capacity to cleave 5’ to 
the AP site, than 3’ to the 3’dRP product. Indeed, Chen et al., 1991 demonstrated that 
mammalian APE1 exhibits 100- to 200-fold higher AP endonuclease than 3’-
phosphodiesterase activity, underscoring the fact that most of the 3’OH product generated 
has resulted from APE1’s ability to cleave 5’ to the AP site directly. However, due to the 
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high activity of APE1, it is not possible to achieve full inhibition of APE1, without 
affecting and inhibiting other essential DNA repair processes, as discussed earlier in 
section 5.2. Thus, the ~30% increase in the 3’dRP products can only provide an idea of 
how much of the 3’dRP product is in fact further processed, without determining the 
actual contribution of NTH1.  
 
Another interesting observation was the increase in the 3’OH products in TDP1 KD 
extract compared to control extract, which might suggest an up-regulation of APE1. 
When TDP1 levels are down-regulated, it is likely that alternate repair enzymes, like for 
instance APE1 gets up-regulated that in turn could explain the increase in 3’OH products. 
Another possible explanation to the increase in the 3’OH may be that TDP1 competes 
with APE1 for binding of the substrate, resulting in less substrate available for APE1. 
When TDP1 is down-regulated, APE1 is able to process the substrate that would normally 
be handled by TDP1, which in turn result in an increase in the 3’OH products. However, 
to confirm any up-regulation of APE1, experiments must be performed on a quantitative 
and qualitative level too.  
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5.5 Comparison of AP site processing in mice and humans 
The processing of intact AP site using mice extracts or extracts prepared from HeLa S3, 
showed similar results; The 3’OH product was most abundant, whereas the 3’P and 
3’dRP products were observed to a lesser extent. The processing of a nicked AP site in 
both model systems suggests that enzymes other than APE1, such like TDP1 are capable 
of processing the 3’dRP terminus generated by NTH1. 
 
As mentioned earlier, Lebedeva et al., 2011 have already demonstrated that recombinant 
TDP1 processes the 3’dRP termini, however the in vitro significance was further 
addressed by using whole-cell extracts 
from mice and immortalized human 
cells in this study. Overall, the activity 
of Tdp1 in whole-cell extracts from 
mice not only supports the findings 
shown by Lebedeva et al., 2011 but 
also suggest that Tdp1 is capable of 
working downstream of Nth1 in a 
similar APE-independent manner as 
shown in S. pombe by Nilsen et al., 
2012. Similar TDP1 activity was also 
observed in HeLa S3 cells, suggesting 
that NTH1 may in concert with TDP1 
and PNKP serve as back-ups for 
APE1 in the repair of AP sites (Figure 
5.1). The in vivo significance of Tdp1 
in S. pombe and chicken DT40 cells, 
have also been established using cell-
based survival assays where Tdp1-
deficient cells were hypersensitive to 
methyl methanesulfonate (MMS), 
underscoring the importance of Tdp1 in 
the AP site repair (Murai et al., 
2012;Nilsen et al., 2012). 
 
Figure 5.1. Possible BER of AP sites in mammals. When 
BER is initiated by NTH1, APE1 is mainly responsible for 
the further processing of the β-elimination product (Black 
arrows). However, an APE-independent pathway has been 
proposed in mammals where TDP1 can process the β-
elimination product generated by NTH1, and thus act as a 
back-up for APE1.  Figure modified from (Wiederhold et al., 
2004) 
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5.6 Conclusion 
Processing of AP sites in mammalian cells was investigated to gain better insight in the 
actions of BER enzymes. Processing of AP site opposite different bases using either mice 
extracts or recombinant NTH1, indicates that the processing of AP site was not affected 
by the opposite base.  
 
The processing of the intact AP site using mice extracts or extracts prepared from HeLa 
S3 cells showed that APE1 is responsible for the main AP site incision activity, whereas 
the roles of NEIL1 and NEIL2 in AP site processing was demonstrated to be non-
essential. The product of NTH1 incision, 3’dRP, was also observed in both mice and 
HeLa S3 extracts, although in lesser extent than the 3’OH product, indicating that NTH1 
is involved in AP site processing. In addition, NTH1 was shown to require 10-fold more 
enzyme to process the 5’dRP terminus than the intact AP site, indicating that NTH1 most 
likely do not compete with POL β for processing of the 5’dRP terminus, downstream of 
APE1. 
 
Down-regulation of NTH1 was not achieved when siRNA specific for NTHL1 gene was 
transfected into HeLa S3 and HaCaT cell lines. TDP1 was, however, successful down-
regulated by ~65% in HeLa S3 cells, and biochemical analysis showed abrogation of the 
3’P product , indicating that TDP1 is to some extent involved in AP site processing. The 
3’dRP termini was shown also to be further processed to the 3’P termini by TDP1 in both 
HeLa S3 cells and mice extracts, indicating that TDP1 is capable of working downstream 
of NTH1 in an APE1-independent manner and thus may serve as a back-up for APE1 in 
the repair of AP site.  
  
  5 Discussion 
 
80 
 
5.7 Future aspects  
The total contribution of NTH1 in AP site processing was not possible to determine 
exactly, since the 3’dRP product is also further processed by other enzymes in the cellular 
extracts. Thus, to clarify the exact role of NTH1 in AP site repair, it is possible to use 
Nth1 KO mice models that have been used in several studies, and are viable with no 
obvious phenotypical changes (Takao et al., 2002).  
Although the processing of AP sites have been investigated and suggest that TDP1 may 
work downstream of NTH1 in an APE1-independent manner in both mice and humans, 
further investigations are required in KD or KO cells to establish its exact role in AP site 
repair. To our knowledge, the involvement of TDP1 in repair of AP sites induced by the 
classical alkylating agent MMS, has not been reported. However, cell-based survival 
assay performed on Tdp1-deficient DT40 cells in chicken demonstrated hypersensitivity 
towards MMS exposure (Murai et al., 2012). MMS produces alkylated bases that are 
converted to AP sites by DNA glycosylases or by spontaneous base loss (McCullough et 
al., 1999). Thus, similar cell-based studies should also be performed using KD or KO 
cells from human cell lines, to determine any changes in cell sensitivity towards MMS 
exposure.  Such cell-based survival assay was intended to be performed on both NTH1 
KD cells and TDP1 KD cells, but due to the unsuccessful down-regulation of NTH1 and 
the lack of time, these experiments were postponed.  
Since the down-regulation of NTH1 was not reproduced after the initiating testing of 
transfection conditions, it is clearly a need to further optimize the transfection conditions 
and also to reconsider the use of the particular NTHL1-siRNA sequences used to down-
regulate NTH1. In addition, cells transfected with either a plasmid expressing GFP or 
fluorescent labeled siRNA, should be included in the experiments to determine the 
transfection efficiencies. Another important factor to consider is whether one should 
rather invest in stable transfection, instead of transient, especially if the time frame 
provided allows it.  
Overall, based upon our results, it is evident that although APE1 is responsible for the 
main AP site processing in mammalian cells, NTH1 and TDP1 are also involved. Further 
investigation of their role in different human and mouse models are thus required since 
increased knowledge of the AP site repair might contribute to unravel the causes of 
human diseases. 
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Appendix A: Recipes of buffers and solutions  
 
Solutions needed for purification 
of enzymes 
 
LB-medium 25 g Difco LB Broth, Miller in 1l MQ 
LB-kanamycin 25 g/l Difco LB Broth, 50 mg/l kanamycin 
LB-sorbitol medium 25 g/l Difco LB Broth, 91 g/l sorbitol, 0.4 g/l betain 
LB-kanamycin medium plates 25 g/l Difco LB Broth, 20 g/l agar, 50 mg/l kanamycin 
Buffer A/B/C 50 mM Na2HPO4, pH 8.0, 300 mM NaCl, 
10 mM β-mercaptoethanol, 10/50/300 mM imidazole 
Solutions needed for SDS PAGE  
Comassie Blue staining solution 40 % methanol, 10 % acetic acid, 0.1 % Coomassie Blue 
Destaining solution 40 % methanol, 10 % acetic acid, 4 % glycerol 
Solutions needed during 
transfection and harvesting cells 
 
Cryo-medium 50% FBS, 10% DMSO in DMEM 
Culture medium  10% FBS, 2% 100x GlutaMAX™, 2% Pen-Strep, 2g/l glucose 
in DMEM . 
Protein-cracking buffer 2x NuPAGE
®
 LDS Sample Buffer, 200 mM DTT 
Lysis buffer 150 mM NaCl, 1% IPEGAL
® 
CA-630, 0.5% DOC, 0.1% SDS, 
1 mM PMSF, 1 mM protease inhibitor cocktail  
1 mM Protease inhibitor cocktail 1.5 mM Benzamidine, 2 mg/l pepstatin A (stock made in DMF) 
and 2 mg/l leupeptin. 
Solutions needed for Western blot  
PBS-Tween buffer 1xPBS, 0.05% Tween
®
20 
Drymilk –blocking buffer 5% or  3% Skim Milk Powder in 1xPBS 
Stripping buffer 20 ml 10% SDS,12.5 ml 0.5 M Tris-HCl pH 6.8, 0.8 ml β-
mercaptoethanol , 67.5 ml MQ 
Solutions needed during activity 
assay 
 
MOPS buffer 50 mM MOPS pH 7.4, 1 mM EDTA, 100 mM KCl, 1 mM 
DTT 
Dilution buffer 20 mM Hepes pH 7.4, 100 mM KCl, 1 mM EDTA, 2 mM 
DTT, 0.1 µg/µl BSA, 20% glycerol 
5xTDP1 buffer 750 mM KCl, 50 mM Tris-HCl pH 7.5, 5 mM EDTA, 5 mM 
DTT 
Tris-sucrose buffer 84% sucrose, 40 mM Tris pH 8, 10 mM EDTA 
5xReaction buffer 350 mM MOPS pH 7.5, 5 mM EDTA, 25% glycerol, 5 mM 
DTT 
Tris-sucrose/MOPS buffer 20% Tris-sucrose buffer, 80% MOPS buffer 
20%  denaturing gel (For one 10x8 
cm gel) 
7 M urea (2.1 g), 0.25 ml 20xTaurin buffer, 2 ml Long 
Ranger™ Gel Solution, 1 ml MQ, 25 µl 10% APS, 2.5 µl 
TEMED 
20 % denaturing sequencing gel 7 M Urea (26 g), 3 ml 20xTaurin buffer or 6 ml 10xTBE 
buffer, 24 ml Long Ranger™ Gel Solution, 14 or 11 ml MQ, 
400 µl 10% APS, 40 µl TEMED 
Formamide loading dye 5% Bromophenol Blue, 5% Xylene Cyanol, 10 mM EDTA in 
formamide   
1xTBE 90 mM Tris Base, 90 mM Boric acid, 2 mM EDTA (pH 8.0) 
Solutions needed for mycoplasma 
detection 
 
10x DNA Loading Buffer 30 % Glycerol, 20 mM EDTA, 0.01 % Bromophenol Blue 
1 % Agarose 0.5 g Agarose, 50 ml 0.5 x TBE, 1.5 µl SYBR Safe 
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Appendix B: Protocol, PCR Mycoplasma Test Kit II 
Derived from: http://www.promocell.com/fileadmin/promocell/PDF/PK-CA20-700-20.pdf 
  
Ready-to-use PCR Mix PK-CA20-700-10 
 
Protocol:  
A. Test sample preparation:  
Transfer 0.5-1.0 ml cell culture supernatant into a 2 ml centrifuge tube. To pellet cellular 
debris, centrifuge the sample at 250 x g briefly. Transfer the supernatant into a fresh 
sterile tube and centrifuge at 15,000-20,000 x g for 10 minutes to sediment mycoplasma. 
Carefully decant the supernatant and keep the pellet (the pellet will not always be 
visible). Re-suspend the pellet with 50 μl of the Buffer Solution and mix thoroughly with 
a micropipet. Heat at 95 ˚C for 3 minutes. The test sample can be stored at this stage at -
20°C for later use.  
  
B. PCR amplification:  
1. Prepare the reaction mixture in a PCR 
tube by combining the reagents shown 
below: Reagents  
Volume  
H
2
O  35 μl  
Reaction Mix  10 μl  
Test sample  5 μl  
 
2. If not using a thermal cycler having a heated lid, overlay mixture 
with mineral oil (approximately 40 μl) to avoid evaporation of the 
reaction mixture. 
 
3. Place all tubes in a PCR thermal cycler. Set the parameters for the 
following conditions and perform the PCR. 
94°C 30 seconds 
94°C 30 seconds 
60°C 120 seconds  35 cycles 
72°C 60 seconds 
94°C 30 seconds 
60°C 120 seconds 
72°C 5 min 
 
C. Analysis of amplified products by gel electrophoresis:  
1. Apply 20 μl of the PCR product onto an agarose gel for electrophoresis. Do not add 
loading buffer to the samples. Use a 2% agarose gel.  
2. Perform agarose gel electrophoresis with the PCR-amplified samples to verify 
the amplified product and its size. The size of DNA fragments amplified using 
the specific primers in this kit is around 270 bp (± 270 bp; depending on the 
mycoplasma species).  
 
D. Control Template:  
To check PCR efficiency use 1 μl of the “Positive Template Control” as a test sample. The 
size of the PCR product obtained using the positive template with primer pairs is 270 bp. *If 
desired, you may add 4 μl 1X Gel Loading Buffer containing a 
marker dye (e.g. bromophenol blue) to the samples.  
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Appendix C: Protocol, Forward Transfection 
Derived from:  
http://www.invitrogen.com/etc/medialib/en/filelibrary/pdf.Par.34731.File.dat/Transfecting_Stealth_usi
ng_Lipofectamine_RNAiMAX.pdf 
 
Forward transfection  
Use this procedure to forward transfect Stealth
™ 
RNAi or siRNA into mammalian cells in a 24-well 
format (for other formats, see Scaling Up or Down Transfections). In forward transfections, cells are 
plated in the wells, and the transfection mix is generally prepared and added the next day. Optimize 
transfections as described in Optimizing Transfections, especially if transfecting a mammalian cell line 
for the first time. All amounts and volumes are given on a per well basis.  
Note: For some cell lines, we recommend reverse transfections. 
 
1. One day before transfection, plate cells in 500 μl of growth medium without antibiotics such that 
they will be 50-70% confluent at the time of transfection. 
 
2. For each well to be transfected, prepare RNAi duplex-Lipofectamine
™ 
RNAiMAX complexes as 
follows:  
a. Dilute 6 pmol RNAi duplex in 50 μl Opti-MEM
®
I Reduced Serum Medium without serum. Mix 
gently.  
b. Mix Lipofectamine
™ 
RNAiMAX gently before use, then dilute 1 μl in 50 μl Opti-MEM
® 
I Reduced 
Serum Medium. Mix gently.  
c. Combine the diluted RNAi duplex with the diluted Lipofectamine
™ 
RNAiMAX. Mix gently and 
incubate for 10-20 minutes at room temperature.  
 
3. Add the RNAi duplex-Lipofectamine
™ 
RNAiMAX complexes to each well containing cells. This 
gives a final volume of 600 μl and a final RNA concentration of 10 nM. Mix gently by rocking the 
plate back and forth.  
 
4. Incubate the cells 24-48 hours at 37°C in a CO
2 
incubator until you are ready to assay for gene 
knockdown. Medium may be changed after 4-6 hours.  
 
Optimizing Transfections  
To obtain the highest transfection efficiency and low non-specific effects, optimize transfection 
conditions by varying RNAi duplex and Lipofectamine
™ 
RNAiMAX concentrations. Test 0.6-30 pmol 
RNAi duplex (final concentration 1-50 nM) and 0.5-1.5 μl Lipofectamine
™ 
RNAiMAX for 24-well 
format. For extended time course experiments (> 72 hours), consider a cell density that is 10-20% 
confluent 24 hours after plating.  
Note: The concentration of RNAi duplex required will vary depending on the efficacy of the duplex.  
Scaling Up or Down Transfections  
To transfect cells in different tissue culture formats, vary the amounts of Lipofectamine
™ 
RNAiMAX, 
RNAi duplex, cells, and medium used in proportion to the relative surface area, as shown in the table. 
 
Culture vessel   Rel. surf. area
1
  Vol. of plating 
medium  
Dilution 
medium reverse 
transfection  
 Dilution 
medium forward 
transfection  
 RNAi (pmol)   RNAi (nM)   Lipofect-
amine
™ 
RNAiMAX
2
 
  
 96-well   0.2   100 μl   20 μl   2 x 10 μl   0.12-6   1-50   0.1-0.3 μl    
 48-well   0.4   200 μl   40 μl   2 x 20 μl   0.24-12   1-50   0.2-0.6 μl    
 24-well   1   500 μl   100 μl   2 x 50 μl   0.6-30   1-50   0.5-1.5 μl    
 6-well   5   2.5 ml   500 μl   2 x 250 μl   3-150   1-50   2.5-7.5 μl    
 60 mm   10   5 ml   1 ml   2 x 500 μl   6-300   1-50   5-15 μl    
 100 mm   30   10 ml   2 ml   2 x 1 ml   12-600   1-50   15-35 μl    
 
       Continues on the next page 
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Figure C.1. Useful numbers used in passaging and transfection of the cells. 
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Appendix D: Protocol, Novex® Semi-Dry Blotting  
Derived from: http://tools.invitrogen.com/content/sfs/manuals/novex_semidry_blotter_man.pdf 
Equilibrating the Gel 
Equilibrating the gel in transfer buffer removes salts that may increase conductivity and heat during 
transfer. Be careful to equilibrate for the recommended time, as longer equilibration can result in 
protein diffusion. 
1. After electrophoresis, remove the gel from the cassette. 
2. Place the gel in a shallow tray containing 100 ml (for Midi Gels and E-PAGE™ Gels) or 50 
ml (for Mini Gels) of the appropriate 2x NuPAGE
®
 Transfer Buffer. Equilibrate for 10 
minutes on an orbital shaker. 
PVDF 
1. Use a pre-cut Invitrolon™/Filter Paper Sandwich or cut a PVDF membrane to the appropriate 
size for your gel. 
2. Pre-wet the membrane for 30 seconds in methanol, ethanol, or isopropanol. Briefly rinse the 
membrane in deionized water. 
3. Soak the membrane in the appropriate Transfer Buffer for a few minutes in a shallow tray. 
 
                                 
Semi-Dry Blotting Protocol 
 
Follow the instructions below to blot 1–2 Midi Gels or 1–4 Mini Gels using the Novex® Semi-Dry 
Blotter: 
1. In a shallow tray, briefly soak 2 stacked pieces of 3-mm thick Blotting Filter Paper in the 
appropriate Transfer Buffer. 
2. Remove any air bubbles trapped between the filter paper sheets by rolling the stack with a 
blotting roller while it is still submerged in buffer. Note:  Removing air bubbles is essential, 
as they can block the transfer of biomolecules. 
3. Place the stack of pre-soaked Blotting Filter Paper on the anode plate of the Novex® Semi-
Dry Blotter. Remove any air bubbles between the paper and plate by rolling the stack with the 
blotting roller. 
4. Place the pre-soaked blotting membrane on top of the Blotting Filter Paper stack and remove 
any air bubbles with the blotting roller. 
5. Carefully remove the gel from the transfer buffer and place on top of the blotting membrane. 
(Gently remove any air bubbles with the blotting roller or a wet gloved finger. Note:   Be 
careful not to disturb the gel after it has been placed on the membrane. Moving the gel can 
result in protein smearing on the membrane.  
6. Briefly soak the remaining 2 stacked pieces of 2.5-mm thick Blotting Filter Paper in the 
appropriate Transfer Buffer. Remove any air bubbles with the blotting roller while the stack is 
still submerged in buffer. 
7. Mini or Midi Gels: Transfer at 20 V for 30–60 minutes. 
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Appendix E: Protocol, High Capacity RNA-to-cDNA  
Derived from: http://tools.invitrogen.com/content/sfs/manuals/cms_050470.pdf  
 
 
Figure E.1. Protocol, High Capacity RNA-to-cDNA Master Mix. 
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Appendix F: Mycoplasma detection in HeLa S3 cells 
and HaCaT cells 
 
 
Figure F.1. Mycoplasma detection using PromoKine’s PCR mycoplasma Test Kit II. 5 µl 
GeneRuler™ DNA ladder mix was used as DNA marker. The size of the PCR product detected is 
270 basepairs.
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Appendix G: Standard curves generated using ACTB 
and NTHL1 primers 
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Figure G.1. HeLa S3 cells were transfected in triplicates with siRNA targeting NTHL1 and non-targeting 
siRNA. After 48 h, cells were harvested, RNA was purified and RT-PCR was performed on cDNA samples 
prepared from non-targeting siRNA-transfected cells, using primers specific for the reference gene ACTB 
(blue) and NTHL1 (green). Standard curves were constructed by plotting CT values of standard dilutions 
against the logarithm (log) of the amount of cDNA template.  
Figure G.2. Melting curve analysis was performed on RT-PCR products using (A) NTHL1 primers and 
cDNA template prepared from cells transfected with NTHL1-siRNA or (B) ACTB primers and cDNA 
template prepared from cells transfected with non-targeting control siRNA. Analysis was performed in 
triplicates. All three replicates overlap in a single peak, showing the specificity of the PCR and the absence 
of primer-dimers. 
